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The EWSR1-FLI1 t(11;22)(q24;q12) translocation is the pathognomonic genomic 
alteration in 85% of the Ewing Family of Tumors (EWFT) a malignancy of the bone and 
the surrounding tissue, predominantly affecting children and adolescents.  This 
translocation results in the formation of a chimeric oncoprotein which acts as an aberrant 
transcription factor that is currently not pharmaceutically druggable, driving the need for 
more effective targeted therapies.  The EWSR1-FLI1  translocation induces a variety of 
changes including dysregulation of the epigenome and altered gene expression to drive 
tumorigenesis, and consequently contributes to the hypersensitivity of EWFT to several 
xiv 
classes of chemotherapeutics.  We sought to exploit these intrinsic sensitivities by 
employing a matched pair of cell lines derived from the same patient with Ewing sarcoma 
prior to and following chemotherapy, a panel of Ewing sarcoma cell lines, and several 
patient-derived xenografts (PDX) collected at the time of relapse or autopsy, which led us 
to the development of two novel combination targeted therapies for EWFT.   
In our matched pair of EWFT cell lines, we found sensitivity to the Poly(ADP-
ribose Polymerase (PARP) inhibitor olaparib was diminished following chemotherapy, 
despite a predicted sensitivity. In addition, we discovered increased expression of the 
antiapoptotic protein BCL-2 in the chemotherapy-resistant cells, conferring apoptotic 
resistance to olaparib. We found that EWS-FLI1 increases BCL-2 expression; however, 
inhibition of BCL-2 alone is insufficient to sensitize EWFT cells to olaparib, revealing a 
dual necessity for BCL-2 and BCL-XL (BCL2L1) in EWFT survival. These data reveal 
BCL-2 and BCL-XL act together to drive olaparib mediated apoptotic resistance in Ewing 
sarcoma and identify a novel, rational combination therapy using olaparib and the BCL-
2/BCL-XL inhibitor navitoclax. 
In addition, using high throughput drug screening we have identified a novel 
epigenetic susceptibility in EWFT to GSK-J4 (GlaxoSmithKline), an inhibitor of lysine 27 
of histone 3 (H3K27) demethylases: ubiquitously transcribed tetratricopeptide repeat, X 
chromosome (UTX) and Jumonji D3 (JMJD3).  Treatment with GSK-J4 leads to a 
decrease in H3K27 acetylation (H3K27ac) and ultimately, the silencing of EWS-FLI1 gene 
targets.   
xv 
We sought to sensitize GSK-J4-mediated inhibition of EWS-FLI1 targets by 
blocking RNA polymerase II activity using the Cyclin Dependent Kinase 7 (CDK7) 
inhibitor THZ1. By targeting CDK7-mediated transcription we were able to sensitize 
EWFTs to H3K27 demethylase inhibition. We therefore propose co-targeting of H3K27 
demethylases and CDK7 acts as a surrogate EWS-FLI1 inhibitor. Given the difficulties 
targeting EWS-FLI1, these strategies may present viable clinical therapies. 
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CHAPTER 1 - Introduction 
 
 
 
 
Targeted Cancer Therapies  
For many decades, systemic chemotherapy has been the cornerstone of cancer 
treatment despite toxicity, low therapeutic indexes, and challenges in drug discovery (1-3).   
Recent advances in molecular profiling and genomics have led to a greater understanding 
of cancer biology (4-6), allowing for the optimization of treatment using targeted therapies 
(7-9).  This technological revolution has led to the emergence of new studies aimed at the 
systemic mapping of cancer genomics and the characterization of pharmacological 
vulnerabilities (10, 11).  These include programs such as the Cancer Genome Atlas 
(TCGA) , the Cancer Cell Line Encyclopedia (CCLE), and the Genomics of Drug 
Sensitivity in Cancer (GDSC) (12, 13), which have helped to identify many of the genes 
responsible for disrupting the cellular processes which lead to cancer.  Despite the 
complexities found in cancers, they are often driven by specific genetic aberrations known 
as oncogenes, whose direct inhibition can have a dramatic effect on cancer growth and 
survival (14, 15).  This “oncogene addiction” serves as the rationale behind the 
development of targeted therapies, aimed at the pharmaceutical impairment of cancer 
specific oncogenes.  Targeted therapies are effective due to their low toxicity and highly 
specific anti-tumor activity in a cytotoxic or cytostatic manner.  This is accomplished by 
designing drugs that target oncogenes specific to each cancer type, which by definition are 
more heavily relied on by cancer cells for survival compared to normal healthy cells (1).    
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One of the first and most significant of these targeted therapies is imatinib mesylate 
(Novartis) (16).  Imatinib is a small molecule kinase inhibitor with specificity for BCR-
ABL, the fusion protein resulting from a chromosomal translocation which drives 
oncogenesis in chronic myeloid leukemia (CML) (17). Imatinib has been employed to 
successfully treat CML while having little effect on normal cells, demonstrating its 
specificity and effectiveness as a targeted therapy (18).  Unfortunately, a common 
occurrence in cancer is acquired resistance which becomes problematic for single agent 
targeted therapies, driving the need to develop and implement new generations of 
inhibitors with higher efficacy and the employment of combination targeted therapies (3, 
7).   
 
The Ewing Family of Tumors  
The Ewing Family of Tumors (EWFT) are the second most common form of 
pediatric bone cancer, with ~250 new cases diagnosed in the United States each year (19) 
and accounts for roughly one-third of all pediatric bone tumors (20).  The malignancy was 
first described in 1921 by its namesake James Ewing, where it was distinguished as a 
separate disease from osteosarcoma and identified as being highly sensitive to radiation 
therapy (21).  The Ewing Family of Tumors consists of Ewing Sarcoma of the bone (ES), 
Extraosseous Ewing Tumors (22), and Peripheral Primitive Neuroectodermal Tumors 
(PNET), all of which share a common family of translocations.  These translocations 
consist of the amino terminus of one the FUS/TLS, EWSRI and TAF15 (FET) family of 
RNA-binding proteins fused to the carboxy terminus of one of the E26 transformation-
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specific (ETS) family of transcription factors.  This fusion results in the formation of 
proto-oncogenes which display neomorphic functions which deregulate the transcriptome 
and epigenome of cells and have been identified as the driving force behind EWFT 
tumorigenesis. (23).  This is accomplished through FET/ETS oncoproteins binding to ETS 
gene targets at GGAA binding motifs located within enhancer or promoter regions, which 
results in chromatin remodeling that alters gene expression (24-26) and to a lesser known 
extent results in the downregulation of tumor suppressors (27, 28).   
Occurrence rates are higher in the male population compared to female (sex ratio of 
1.5:1) and is predominantly higher among Caucasians, with a much lower incidence in 
people of Asian and African descent.  Of note, there is a difference in the size and 
grouping of the GGAA ETS binding motifs found between Caucasian and African/Asian 
populations which may help explain the observed differences in disease frequency.  
However, within all population’s a high number of GGAA microsatellites occur at ETS 
target genes, with 20-26 repeats found in European samples and 30 or more in African 
samples.  These  greater numbers of GGAA consecutive repeats may be attributed to a 
more aggressive phenotype and help explain the lower survival rates found in African 
populations despite their decreased rate of occurrence.  Despite these findings, a possible 
genetic distinction between the 10 fold greater rate of occurrence in people of European 
ancestry still remains unclear (24, 25, 29, 30).  
  Recent advances have been made in the treatment of primary EWFT tumors using 
systemic chemotherapy to increase the 5-year survival rate to 70%. Unfortunately, 25% of 
patients are asymptomatic for micrometastasis at the time of diagnosis and these patients, 
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or those who relapse following chemotherapy have a 5-year survival rate of less than 30% 
(19, 31).  The current standard of care (VDC-IE: Vincristine, Doxorubicin, 
Cyclophosphomide – Ifosfamide and Etoposide) for EWFT in North America relies 
heavily on adjuvant and neoadjuvant systemic chemotherapy followed by surgical 
resection of the primary tumor and continued chemotherapy or radiation therapy (32-34).  
In a study by the Children’s Oncology Group (COG), the event free survival (EFS) was 
significantly increased in patients treated with a more intense regimen of VDC-IE 
chemotherapy at 2-week intervals compared to patients treated at 3-week intervals (COG-
AEWS0031 [NCT00006734]), which suggests more aggressive treatment regimens are 
necessary for improved patient outcomes.  Due to the aggressive nature of the disease, a 
high prevalence of metastasis/relapse and the intense chemotherapy treatments required, 
there exists a dire need to develop more potent and effective targeted therapies.   
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FET/ETS Fusion Chromosomal Translocation Frequency
EWSR1-FLI1 t(11;22)(q24;q12) ~85%
EWSR1-ERG t(21;22)(q22;q12) ~10%
EWSR1-ETV1 t(7;22)(p22;q12) <1%
EWSR1-ETV4 t(17;22)(q12;q12) <1%
EWSR1-FEV t(2;22)(q35;q12) <1%
FUS-FEV t(2;16)(q35;p11) <1%
FUS-ERG t(16;21)(p11;q24) <1%
 
Table 1.1 Fusions which result in EWFT. 
 
EWS 
EWS is a nuclear protein encoded by EWS RNA binding protein 1 (EWSR1) and is 
a member of the FET family of RNA binding proteins.  Within this family are Fused in 
Sarcoma (FUS), EWSR1, TATA-Box binding protein Associated Factor 15 (TAF15), and 
translocations of these FET family of genes has been associated with a number of diseases  
(31, 35, 36).  The carboxy-terminus of EWS consists of its RNA binding domain and is 
responsible for its ability to interact with RNA splicing factors while the amino-terminus 
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of EWS contains a transcription activation domain which is maintained in translocations 
that result in EWFT.  EWS is considered an intrinsically disordered protein (IDP) due to its 
repetitive (SYGQQS) low complexity amino acid sequence Prion-like domain, located 
within the transcriptional activation region of the N-terminus, and is hypothesized to allow 
for its transcriptional activation through the process of multimerization (37, 38).  This 
subsequent multimerization allows for the aggregation of EWSR1 and imbues phase 
transition properties which are essential for the stabilization required to recruit co-
activators and the chromatin remodeling complex BRG1/BRM-associated factor (BAF) to 
induce the gene activation profiles associated with EWFT when translocated (39-41).   
 
ETS 
The ETS (E26 Transformation-Specific) family of transcription factors was first 
discovered and initially named while researching the avian erythroblastosis virus, E26 in 
1983 (42).  This group contains 28 transcription factors in humans that all share a highly 
conserved DNA binding domain (ETS domain), consisting of a winged helix-turn-helix 
which binds the major groove, making it critical for a vast majority of cellular processes as 
they occupy 15% of all human promoters and regulate pathways responsible for cell cycle 
regulation, differentiation, proliferation, and apoptosis  (30, 43-45). In addition, knocking 
out the ETS family member: Friend Leukemia Integration 1 transcription factor (FLI1) has 
proven to be embryonic lethal demonstrating its importance in development  (46, 47).  For 
these reasons the ETS family members are often implicated in the tumorigenesis of 
multiple cancer types (43-45, 48, 49).  This often occurs through their direct amplification 
7 
or as a result of gene fusions such as TMPRSS2/NDRG1-ERG (transmembrane protease 
serin2/N-Myc downstream regulated 1 - ETS-related gene) in prostate cancer (50) and 
EWSR1-ETS in Ewing Sarcoma.  In addition to the DNA binding domain, many ETS 
family members possess an additional pointed (PNT) domain, which plays a role in 
protein-protein interaction, however the PNT domain in FLI1 is lost in the EWS-FLI1 
translocation  (43, 48, 49, 51).   
 The EWSR1-FLI1 translocation is present in 85% of all EWFT cases, while the 
remaining 15% harbor EWSR1-ERG t(21;22)(p22;q12), EWSR1-ETV1 t(7;22)(p22;q12), 
EWSR1-ETV4 t(17;22)(q12;q12), or EWSR1-FEV t(2;22)(q33;q12) translocations (44, 52, 
53).  Both FLI1 and ERG expression is relatively low in adult tissues, however they are 
highly expressed in both the spleen and bone marrow due to their role in hematopoiesis 
(47, 54).  In addition, the FLI1 and ERG transcription factors involved in EWFT have been 
shown to induce very similar clinical phenotypes and gene expression changes, likely due 
to only minor differences in their N terminus, suggesting they share gene targets and serve 
similar functions that contribute to disease when translocated to EWSR1 (27, 55).     
 
EWS-FLI1 
Within the Ewing Family of Tumors the majority are driven by the specific 
EWSR1-FLI1 t(11;22)(q24;q12) translocation event, which results in the DNA binding 
domain of FLI1 fused to and regulated by the strong transcriptional activation domain of 
EWSR1 (27, 56-60).  FLI1 was first identified over 20 years ago, where it was quickly 
found to represent the dominant translocation event which causes Ewing Sarcoma (Fig. 
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1.1).  The resulting EWS-FLI1 fusion retains a more potent level of transcriptional activity 
compared to the wild type FLI1 which has a relatively weak transcriptional activation 
domain (61).  The remaining 15% of EWFTs harbor alternative EWS-ETS fusions whose 
functions mimic that of EWS-FLI1 (45, 49).  Both EWSR1 and FLI1 are required for 
transformation, as deleting portions of either gene results in a loss of the transformation 
phenotype (25).   
In addition to the gene specific chimeric fusion, there are subtypes of each 
translocation determined by the breakpoint regions of EWSR1 and FLI1.  The most 
common EWS-FLI1 transcript variant is that of EWSR1 exon 7 fused to FLI1 exon 6 (7/6 
fusion), and is known as type 1 (62).  These specific EWS-FLI1 oncoprotein subtypes were 
previously reported to influence factors such as the tumorigenicity and propensity to form 
metastasis (63, 64).  However, more current studies have refuted this claim, suggesting that 
the fusion subtype has no effect on clinical phenotypes (52, 65).   Recent studies have 
shown that the EWS-FLI1 translocation is not only required for EWFT tumorigenesis, but 
its expression is able to transform mesenchymal stem cells (MSCs), the proposed cell of 
origin of EWFT.  When the EWS-FLI1 translocation is expressed in pediatric MSCs, a 
gene expression profile is induced which emulates that of EWFT (26, 66, 67). 
 
9 
 
Figure 1.1 EWS-FLI1 
Chromosomal translocation which creates the EWS-FLI1 oncoprotein, binding the TAD of 
EWS to the ETS domain of FLI1.  
 
Cell of Origin 
 Within the EWFT there is a lack of knowledge concerning the most likely cell 
lineage of origin, whose identification would serve to elucidate more reliable markers of 
disease and therapeutic agents.  Early studies have demonstrated that a subset of EWFT 
display neural markers, and expression of the EWS-FLI1 translocation in neuroblastoma 
cells is sufficient to induce a gene expression profile associated with EWFT.  The 
expression of EWS-FLI1 in pediatric mesenchymal stem cells induces the expression of 
genes responsible for neuroectodermal differentiation (57, 68).   However, more recent 
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data suggests EWFT is of mesenchymal origin, and that it may exude a partial neural 
phenotype as a consequence of the EWS-FLI1 reprogramming.    
Riggi and colleagues (69) demonstrated that expression of the EWS-FLI1 
translocation in bone-derived human mesenchymal stem cells (hMSC) alone is enough to 
transform the cells and generate tumors which mimic that of the Ewing Family of Tumors.  
This translocation induces a cellular phenotype analogous to the small round blue cells that 
are the hallmark of EWFT, and a gene expression profile comparable to FLI1 target gene 
expression.   In addition, the knockdown of EWS-FLI1 in EWFT cell lines results in the 
cellular expression of cell surface markers and gene expression profiles closely resembling 
mesenchymal stem cells (26, 66, 67, 70, 71).  Of the various progenitor cell types that have 
been proposed, only mesenchymal stem cells are able to stably express the EWS-FLI1 
fusion.  In addition, the CD99 antigen, which is normally expressed on the surface of 
hMSC is the most widely used histological marker for EWFT detection (72). Taken 
together, this data would strongly suggest that these tumors arise from a mesenchymal 
stem cell of origin. 
 
EWFT Transcriptional Regulation 
 EWS-FLI1 preferentially binds to specific microsatellite motifs consisting of 
repetitive GGAA sequences.  Interestingly, the GGAA core consensus sequence is a direct 
binding target of wild type FLI1, and only the translocated EWS-FLI1 results in the 
activation of de novo enhancer elements.  Gene activation is achieved when GGAA motifs 
contain 4 or more repeats,  and optimal binding is attained at 12-14 repeats (25, 30).  EWS-
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FLI1 has a higher binding affinity to these repeats than wild type FLI1 resulting in FLI1 
displacement and consequential alterations of gene expression (24, 39, 73).  More 
importantly, the presence of multiple GGAA microsatellite repeats has been detected in 
75% of the genes activated by EWS-FLI1, while 85% of genes repressed by this chimeric 
protein displayed non-repetitive GGAA sequences (26).  In addition, the clinical 
phenotypes of other EWS-ETS fusions such as EWS-ERG mimic that of  EWS-FLI1 
suggesting a similar global deregulation of gene expression within EWFT (55).  
 Although the exact functions of EWS is not currently understood, the EWS amino-
terminus is shown to exhibit direct interactions with transcriptional machinery such as 
RNA polymerase II and the co-activator p300/CBP (26, 39, 58, 74, 75).   Both wild type 
EWSR1 and the EWS-FLI1 fusion are able to interact with the BRG1/BRM-associated 
factor (BAF) chromatin remodeling complex which contributes to gene activation.  This 
leads to the recruitment of the BAF complex to tumor-specific enhancers at FLI1 binding 
targets, resulting in their activation  (39).    However, the method of EWS-FLI1 gene 
repression is poorly understood.  It is hypothesized to be an indirect mechanism, through 
miRNA and epigenetic mechanisms which alter post-transcriptional gene regulation, as 
EWS-FLI1 does not bind directly to the enhancers of repressed genes (76, 77).  Another 
possibility is through the Enhancer of Zeste homolog 2 (EZH2), a bona fide EWS-FLI1 
gene target, which is directly upregulated by EWS-FLI1, and is the enzymatic subunit of 
the polycomb repressive complex 2 (PRC2) responsible for methylation of histone 3 
Lysine 27  (78-81).  Increases in methylation at lysine 27 are marks of repressed 
chromatin, and the upregulation of EZH2 suggests a method of EWS-FLI1 mediated 
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indirect gene silencing through the remodeling of chromatin.  It has also been 
demonstrated that wild-type FLI1 binds to single GGAA repeat motifs and once bound is 
capable of recruiting the p300 co-activator.  However, the EWS-FLI1 oncoprotein has a 
higher binding affinity for these GGAA motifs but requires multimerization for p300 and 
BAF recruitment, effectively silencing many EWS target genes with less than 4 GGAA 
motifs (26).   
 
Research Goals 
 The Ewing Family of Tumors serves as an excellent model to study the paradigm 
that chromosomal translocation-driven cancers represent.  Due to the low mutational 
burden found in EWFT and the specific FET-ETS driver events, we are presented with a 
unique transcription factor driven deviation from normal cell regulatory processes (82).  
Unlike many specific oncogene addictions which we are able to pharmaceutically inhibit, 
EWS-FLI1 is not a viable target, however the changes in gene expression that it causes 
represent potential therapeutic targets (20, 58).  The principle goal of our research is to 
investigate and address a means of pharmaceutically targeting the driving force behind 
EWFT pathogenesis: the EWS-FLI1 translocation, through indirect targeting of its 
downstream effects. Taken together, these studies hope to expand upon the mechanisms by 
which the EWS-FLI1 translocation evades traditional therapies, and to develop novel 
targeted therapies which can be utilized in a clinical setting.   
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The work herein evaluates and achieves the following aims: 
1.  Elucidate the mechanism by which EWFT become resistant to Poly(ADP-
ribose) polymerase inhibition (PARPi) and develop a means of countering 
this resistance. EWFT are extremely sensitive to PARPi in vitro due to their 
lack of efficient homologous recombination repair.  However, the PARP1/2 
inhibitor olaparib had little efficacy in a clinical trial comprised of patients with 
chemo-refractory disease (83).  Understanding the disconnect between the 
observed deficiency of PARP inhibitor activity, and the altered gene expression 
profile induced by EWS-FLI1 (which likely contributes to chemotherapy 
resistance), is critical to better understand and develop new targeted therapies 
effective in patients who relapse or acquire drug resistance.   
2. Identify a means of pharmaceutically targeting the vast genomic 
remodeling that occurs as a result of EWS-FLI1.  This work focuses on 
targeting the epigenetic mechanisms that EWS-FLI1 utilizes to dysregulate the 
epigenome.  This refers to DNA modifications which can result in the alteration 
of gene expression without changing the sequence of DNA.  These 
modifications are caused by the methylation of DNA at cytosine residues, the 
remodeling of chromatin, and through modifications to histone tails which 
result in their methylation or acetylation (84, 85).  EWS-FLI1 is capable of 
altering the expression of histone marks at enhancer and super-enhancer 
regions, these resulting changes to the epigenome alter the transcriptional 
activity of genes.  Two of the histone modifications most highly regulated by 
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EWS-FLI1 are H3K27ac and H3K4me1, both ubiquitous markers of active 
enhancers, and are found to be enriched at known EWS-FLI1 gene targets (26, 
76).  By combining histone demethylase and RNAP II inhibitors we sought to 
disrupt the EWS-FLI1 transcriptional machinery and H3K27ac modifications 
which promote EWFT oncogenesis.  
1 
 
 
 
 
CHAPTER 2 – Materials and Methods 
 
 
Cell Lines 
A673 (ATCC® CRL-1598™) and HEK293T cells were cultured in DMEM 
(Gibco) with 10% FBS (Seradigm) and 1µg/ml penicillin and streptomycin. CHLA9 and 
CHLA10 cells were grown in DMEM with 20% FBS, 1ug/ml penicillin and streptomycin, 
and 1% Insulin-Transferrin-Selenium 100x (Gibco). SK-ES-1(ATCC® HTB-86™) was 
grown in DMEM/F12 (Corning) with 15% FBS and 1ug/ml of penicillin -and 
streptomycin. ES4 and EW16 cells were grown in RPMI1640 (Lonza Group) with 10% 
FBS and 1µg/ml of penicillin and streptomycin. Routine mycoplasma testing was 
performed on all cell lines. CHLA9, CHLA10 and the PDX models TX-E-270x and TX-E-
351x were obtained from the Children’s Oncology Group (COG) Cell Culture and 
Xenograft Repository, special thanks to Dr. C. Pat Reynolds, Texas Tech University 
Health Sciences center. PDX models SA10233 and SA13542 were obtained from Crown 
Bioscience.  Ex vivo PDX lines were derived using selective trypsinization (86) over 
consecutive passages and cultured in RPMI 1640 with 10% FBS.   ES4, EW16, HEK293T, 
A673 (ATCC® CRL-1598™), and SK-ES-1 (ATCC® HTB-86™), were obtained from 
either the Molecular Center Therapeutics laboratory at Massachusetts General Hospital 
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which performs routine testing of cell lines using STR and SNP analysis, or from the 
American Type Culture Collection (ATCC). 
 
Antibodies and Reagents 
Primary antibodies used for Western blotting were GAPDH (Santa Cruz sc-3233) , 
RNAP II (Santa Cruz sc-56767), FLI1 (Santa Cruz sc-365294) Santa Cruz Biotechnology 
(Dallas, TX); Cleaved PARP1 (Cell Signaling 5625), BCL-2 (Cell Signaling 4223), BCL- 
XL (Cell Signaling 2764), MCL-1 (Cell signaling 5453), p-Ser2 RNAPII (Cell Signaling 
13499), p-Ser5 RNAPII (Cell Signaling 13523), CCND1 (Cell Signaling 2922), EZH2 
(Cell Signaling 5246), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling 9733), Histone H3 
(Cell Signaling 3638), PARP1 (Cell Signaling 9532), pH2A.X (Cell Signaling 9781), and 
BIM (Cell Signaling 2933) from Cell Signaling Technology (Beverly, MA); FLI1 (Abcam 
ab15289), NPY1R (Abcam ab91262), from Abcam (Cambridge, UK); Acetyl-Histone H3 
(Lys27) (Active Motif 39133), from Active Motif (Carlsbad, CA).  Secondary antibodies 
used were mouse IgG (GE Healthcare Life Sciences NXA931) and rabbit IgG (GE 
Healthcare Life Sciences NA934) GE Healthcare (Little Chalfont, United Kingdom). IgG 
(Santa Cruz sc-2027) for immunoprecipitation was from Santa Cruz Biotechnology 
(Dallas, TX). Olaparib (AZD-2281) was from Abmole (Houston, TX), A-1331852, 
navitoclax (ABT-263) and venetoclax (ABT-199) were kindly provided by AbbVie Inc. 
(North Chicago, IL), GSK-J4 and THZ1 were from Abmole (Houston, TX). 
 
Western Blotting 
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Cell lines and tumor lysates were prepared using standard procedures (87) and lysis 
buffer (50mM Tris, 15mM NaCl, 1%NP-40, 1% SDS, 0.5% NaDOC, 1mM EDTA, 1mM 
EGTA, 10% glycerol, protease and phosphatase inhibitors), incubated on ice for 15 
minutes and centrifuged at 10,000 rpm for 10 minutes. Tumor lysates were homogenized 
using the Tissuemiser (Fisher Scientific) in RIPA lysis buffer (15mM NaCl, 50mM Tris, 
1%NP-40, 1%SDS, 0.5% NaDOC, glycerol, protease and phosphatase inhibitors), followed 
by a 30 minute incubation on ice and 10 cycles of sonication - 30 seconds on 30 seconds 
off (Bioruptor 300, Diagenode). Equal concentrations of lysates were run using the 
NuPAGE Novex Midi Gel system using 4-12% Bis-Tris Gels (Invitrogen), and transferred 
onto PVDF membranes (PerkinElmer). Membranes were blocked in 5% non-fat milk in 
TBST, primary antibodies were incubated overnight. Chemiluminescence was detected 
after incubation with SuperSignal West Femto (Thermo Fisher) using a Syngene G:Box 
camera (Synoptics). 
 
Immunoprecipitation  
Immunoprecipitation experiments were performed as previously described (87).  
A673 cells were lysed using the same buffer for western blotting experiments. 25 µl of 
protein A sepharose beads (GE Healthcare, Bio-Sciences) were added to the lysates 
followed by 0.5 µg of the indicated antibodies: BCL-2 (Cell Signaling 4223),  H3K27ac 
(Diagenode C15410196), or rabbit IgG (Santa Cruz sc-2027). Samples were incubated 
with motion at 4°C overnight. Immunoprecipitated complexes were washed three times in 
the same lysis buffer and for IP’s were run using 4-12% Bis-Tris Gels (Invitrogen), and 
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transferred onto PVDF membranes (PerkinElmer) in parallel with whole cell lysates 
containing 5% of the immunoprecipitation input. Membranes were blocked in 5% non-fat 
milk in TBST, primary antibodies were incubated overnight. Chemiluminescence was 
detected after incubation with SuperSignal West Femto (Thermo Fisher) using a Syngene 
G:Box camera (Synoptics).  For ChIP, immunoprecipitated complexes were fixed using 
1% formaldehyde and isolated, DNA was purified and Quantitative RT-qPCR of primers 
for the 5’ region of the FLI1 binding site of putative enhancers was run on the 7500 Fast 
Real-Time PCR System (Applied Biosystems) measuring fluorescence of SYBR Green 
(Applied Biosystems). Primers used are listed in table 2.1 as described within each chapter.  
Results were normalized to the input chromatin using the Delta-Delta Cycle Threshold 
method. 
 
Immunohistochemistry 
BCL2 IHC was performed on a DAKO Omnis autostainer using Clone 124 
(DAKO; predilute 10 minutes), with high pH antigen retrieval with standard HRP/DAB 
detection, using tonsil control. BCL- XL IHC was performed using a Leica Bond 
autostainer using clone H-5 (Santa Cruz Biotech; 1:250), per manufacturer instructions and 
standard HRP/DAB detection, using manufacturer recommended control. Expression of 
BCL-2 and BCL- XL: Cytoplasmic immunostaining in non-necrotic/preserved areas of 
whole sections was evaluated by surgical pathologist (SCS) in accordance with IRB 
HM20002579 and scored semi-quantitatively as 0 (negative); 1+ (weak positive); 2+ 
(moderate positive); or 3+ (strong positive). Proportion positive was scored as focal 
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(<10%); multifocal (10-50%), or diffuse (>50%). Images were taken using an Olympus 
DP73 using Olympus cellSens imaging, version 1.16. 
 
Immunofluorescence 
Cells were grown in 6-well plates on cover slips.  Cells were treated for 24 hours 
with the indicated drug treatment.  Following completion cells were fixed in cold methanol 
followed by a 10 minute incubation in 0.2% Triton X-100.  Cells were then blocked in 5% 
normal goat serum with 0.1% tween in PBS for 1 hour at room temperature.  Cells were 
incubated with pH2A.X (Cell Signaling 9718S) diluted with antibody buffer (1% BSA in 
0.1% tween in PBS) and incubated in a humid chamber at 4°C overnight.  Following 
incubation, Alexa Fluor 488 labeled antibody was added for 1 hour at room temperature.  
Cells were washed, and the nucleus was stained with DAPI.  Slides were mounted and 
sealed with vectashield and imaged on under a zeiss axio observer 7 fluorescent 
microscope.  Quantification of pH2A.X was performed using matching capture parameters 
in randomly selected regions of interest.  Using ImageJ, images were converted to 
grayscale binary and individual cells were counted and analyzed based on pH2A.X 
fluorescent intensity as RFU (88).   
 
Apoptosis 
Cells were prepared using standard procedures described previously (89) and were 
seeded in triplicate. Cells were treated for 24 , 48, or 72 hours with the indicated drug 
treatment. Following treatment cells were stained with propidium iodide and Cy5-Annexin 
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V and analyzed using the Guava easyCyte FACS machine (Millipore). Cells were 
considered apoptotic if they stained positive for Annexin V alone or Annexin V and 
propidium iodide. 
 
Cell Cycle Analysis 
Cells were seeded in triplicate in 35mm dishes and treated as indicated. After 24 
hours cells were trypsinized and re-suspended in binding buffer with 0.1% Triton in PBS 
and stained with Propidium Iodide, followed by incubation for 20 minutes at 37 °C and 
analyzed using the Guava easyCyte FACS Machine. 
 
Cell Viability Assays 
For CellTiter-Glo assays, dose response curves, and IC50 curves, cells were seeded 
at 3,000 cells per well in 96-well flat bottom black plates and treated the next day in 
quadruplicate with serial dilutions of the indicated drugs. After 72 hours, 25µl of CellTiter-
Glo (Promega) was added to each well and read on a Synergy H1 Hybrid Reader (BioTek). 
For crystal violet staining, cells were seeded at a density of 50,000 cells per well in 35mm 
dishes. The next day cells were treated with the indicated drugs and allowed to grow for 3-
5 days until the control (no rx) well grew to confluency. The cells were then fixed with 
glutaraldehyde (Sigma-Aldrich) and stained with 0.1% crystal violet (Sigma- Aldrich). 
 
Cleaved Caspase-3 Activity Assays 
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Cells were seeded in quadruplicate at 5 x104 in a 96 well plate.  After 24 hours, the 
medium was changed, and cells were treated for 24 hours with the indicated drug 
treatment.  Cells were assayed for caspase-3 activity as per the manufacturer’s protocol 
(Cell Signaling Technology, 5723S).  Plates were read after a 2 hour incubation period.   
 
RNA Isolation and RT-qPCR 
Total RNA was isolated from cells grown at sub-confluency using the Quick-RNA 
MiniPrep Kit (Zymo Research) for olaparib/navitoclax treatments or the Isolate II RNA 
Mini Kit (Bioline) for GSK-J4/TZH1 treatments, and RNA was reverse-transcribed to 
cDNA using the iScript Adv cDNA Kit for RT-qPCR (BIO-RAD) on a GeneAmp PCR 
System 9700 (Applied Biosystems). Quantitative RT-PCR of reported primer sets and β-
actin was run on the 7500 Fast Real-Time PCR System (Applied Biosystems) measuring 
fluorescence of SYBR Green (Applied Biosystems). Primers used as described in each 
chapter are listed in table 2.1.  Results were normalized to ACTB using the Delta-Delta 
Cycle Threshold method. The melting curves of the primers are included in Figure 3.7. 
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Gene Forward Primer Reverse Primer
BCL2 CTGCACCTGACGCCCTTCACC CACATGACCCCACCGAACTCAA
EZH2 GTTCAAAACTCGGGGGTGGT CACCACTAGGAGCGGCCAG
ACTB AGAGCTACGAGCTGCCTGAC AGCACTGTGTTGGCGTACAG
NPY1R CCATCGGACTCTCATAGGTTGTC GACCTGTACTTATTGTCTCTCATC
STEAP1 GGCAATACTGGCTCTGTTGGCT GCGTGTATTGTGCCCAGTAGAAG
PKRCB1 AAAGAGATCCAGCCCCCTTA TATCAGTGGGGGTCAGTTCC
LOX  GCGACGACCCTTACAACC GGACGCCTGGATGTAGTAGG
CCND1 TCGAGAGGCCAAAGGCTGGT GGGGTTTTACCAGTTTTATTTCTAGAC
NPY1R CCATCGGACTCTCATAGGTTGTC GACCTGTACTTATTGTCTCTCATC
NPY1R (ChIP, putative enhancer) TCATCCTTGGGCTTCTGTACC AAGGACCCAGCTGCTTTTCAG
EZH2 AACCCGCAAGGGTAACAAA TGATCACCGTTAACCATCATAACT
EZH2 (ChIP, putative enhancer) CAGCTTTGCGGAAAAACTCCA TGTGGTGGATGAACATCACTCTT
NKX2.2 CAGCGACAACCCGTACAC GACTTGGAGCTTGAGTCCTGA
NKX2.2  (ChIP, putative enhancer) GGCCCCTTGAGACAGGTTGA CCTGAGGCCAAGTTTCCATCC  
Table 2.1 List of Primers 
 
Gene Expression and Knockdown Studies 
The EWS-FLI1 Type1 fusion plasmid (plenti4-FLI1) and Empty Vector (plenti4-
EV) was a gift from Miguel Rivera (26). To knockdown BIM, siRNA transfection was 
performed with Lipofectamine 2000 Transfection reagent (ThermoFisher, 11668-019) and 
Bim siRNA Hs_BCL2L11_5 FlexiTube siRNA (Qiagen, SI02655359). The siRNA ON-
TARGETplus Non- targeting Pool (Dharmacon, D-001810-10-05) was used as a control 
and cells were treated 24 hours after transfection. To over express GFP, BCL-2 and BCL-
XL CHLA10 cells were transfected using Lipofectamine 2000 Transfection reagent 
(ThermoFisher, 11668-019) and GFP in a pCDNA3.1 vector (GenScript), BCL-2 in a 
pcDNA3.1, BCL-XL in a pcDNA3.1 vector.  24 hours after transfection lysates were 
collected to confirm expression and cells were treated with olaparib for 24 hours before 
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measuring viability using CellTiter Glo.  For EWS-FLI1 knockdown experiments, short 
hairpin RNA (shRNA) in a pLKO.1 vector was used (26) in parallel with a shRNA control 
scramble sequence (MISSION pLKO.1-shRNA control plasmid DNA), both shRNA have 
pLKO.1 puromycin-resistant backbones. shRNA transduction methodology has been 
previously described (87).  For siRNA knockdown studies with TP53, siGENOME 
SMARTpool Human TP53 (ThermoFisher, M-003329-03) and siGENOME Control Pool 
Non-Targeting #2 (Dharmacon, D-001206-14-05) were used together with Lipofectamine 
2000 and cells were treated with olaparib 24 hours after transfection.    
 
Animal Experiments 
For xenograft models, 5x106 cells were injected subcutaneously into the flank of 6-
8-week-old Nod/SCID gamma (NSG) mice. The Patient Derived Xenograft Models 
SA10233 and SA13542 were obtained from Crown Bioscience, TXE-270x and TXE-351x 
were obtained from the Childhood Cancer Repository (TXCCR.org), and 5x105 cells were 
injected into the flank of NSG mice subcutaneously. Treatment began when tumors 
reached ~100-200mm3 and mice were randomized into treatment cohorts. Tumor size and 
mouse weight was measured 3 days per week with a digital scale and calipers, where tumor 
volume was calculated as length x width2 x 0.52. Navitoclax and olaparib were 
administered by oral gavage. Navitoclax was dissolved in 60% Phosal 50 PG, 30% 
PEG400, and 10% Ethanol, for a final dosage of 80mg/kg of body weight. Olaparib was 
dissolved in 10% hydroxypropyl-β-cyclodextrin for a final dosage of 100mg/kg of body 
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weight. GSK-J4 and THZ1 were administered by intraperitoneal injection (IP). GSK-J4 
was dissolved into DMSO for a final dosage of 50mg/kg of body weight. THZ1 was 
dissolved 10% DMSO and D5W  for a final dosage of 10mg/kg of body weight.  All drugs 
were administered once per day 5 days/week. For pharmacodynamics studies, tumor 
bearing mice were treated with drug for 3 days, and tumors were harvested on the 3rd day 
2 hours after the final treatment. Tumors were flash frozen in liquid nitrogen.  For the 
blood toxicity study, NSG mice were treated with no drug (No Rx), navitoclax, olaparib, or 
the combination.  At 3 and 7 days mice were exsanguinated, and blood was sent to 
IdexxBioResearch for testing.  The recovery cohort was treated for 7 days and allowed 24 
hours of recovery from treatment before exsanguination.  All animal experiments were 
approved by the Virginia Commonwealth University Institutional Animal Care and Use 
Committee (IACUC protocol#AD10001048). 
 
Dataset Analysis 
The online database for publically accessible drug sensitivity data 
(www.cancerRxgene.org) was used to generate Figure 3.3C. The CCLE (90) was used to 
analyze expression between FLI1 and BCL-2 Figure 3.13D. The data analyzed for MCL-1 
expression among sarcomas (Fig. 3.3D) was obtained from the R2 genomics analysis and 
visualization platform, r2.amc.nl/.    
 
Statistical Considerations 
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For gene expression analyses and the complete blood count analysis (CBC), 
significance was determined using the non-parametric Mann-Whitney U test. Differences 
were considered statistically significant if P < 0.05. All other analyses were performed 
using the Student’s t Test and considered statistically different if P<0.05.  Asterisks 
indicate levels of significance ns(P  ≥  0.05), *(P < 0.05), **(P < 0.01), ***(P < 0.001), 
****(P < 0.0001). 
 
Synergy Assays 
Cells were seeded at 3 × 103 cells in a 96-well plate. 24 hours after seeding, cells 
were treated with varied concentrations of navitoclax (0 to 2 M) and olaparib (0.1 to 10 
M) for 72 hours, or cells were treated with varied concentrations of GSK-J4 (0 to 2.5 M) 
and THZ1 (0.01 to 160 M) for 48 hours followed, by measurement of cell viability by 
CellTiter-Glo. Percent viability was constrained to a maximum of 100. Percent over the 
bliss score was calculated as previously described (91). 
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Chapter 3 - The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape 
PARP Inhibitor Toxicity 
Introduction 
  The driving force behind oncogenesis in EWFT is the EWS-FLI1 translocation, 
which is currently undruggable, and effective targeted therapies for treatment remain 
elusive. Recent findings have highlighted the role EWS-FLI1 plays to induce a wide range 
of changes throughout the epigenome, affecting both histone marks and enhancers (26, 36, 
73, 92, 93), leading to the simultaneous enhanced expression of tumor oncogenes and the 
reduced expression of tumor suppressors (26). However, these studies have yet to reveal 
specific, druggable targets with associated clinically available therapies.  Due to the lack of 
any single druggable gene target responsible for EWFT oncogenesis, we have explored 
two different strategies to treat the disease.   
The first approach is to directly target the epigenetic remodeling triggered by 
EWSR1-ETS fusions, in hopes of reversing their massive cellular reprogramming.  Until 
recently, the mechanisms and full extent of EWS-FLI1 epigenetic reprogramming was 
unknown (24, 26, 39, 76).  These new discoveries paired with the development of highly 
effective drugs capable of targeting histone modifications has paved the way for the 
development of epigenetic targeted therapies in EWFT.  Utilizing these recent discoveries 
which have identified the epigenetic mechanisms of EWS-FLI1 gene activation through 
histone modifications and chromatin remodeling, we explored a strategy to 
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pharmaceutically reverse EWS-FLI1 mediated gene activation.  This approach utilized the 
indirect inhibition of EWS-FLI1 and demonstrated robust anti-tumor efficacy and is further 
discussed in Chapter 4.  
 Our second approach sought to exploit drug sensitivities acquired during EWS-
FLI1 genetic reprogramming.  One consequence of the EWS-FLI1 fusion is an increase in 
DNA-RNA hybrids called R-loops, which are capable of sequestering and inactivating 
BRCA1.  BRAC1 is critical for the repair of double stranded breaks through its interaction 
with RAD51 to influence the repair of DNA and maintain genome stability (56, 94).  The 
sequestered BRCA1 leads to a deficiency in DNA repair, rendering EWFT acutely 
sensitive to DNA damaging agents which have been the focal point of current targeted 
therapy research (95-99). In this chapter, we sought a means of re-sensitizing EWFT to a 
promising class of DNA damaging agents which, despite the predicated sensitivity, EWFT 
tumors were inherently resistant to.  Although the mechanisms of these two approaches 
differ greatly, they both explore unique therapeutic opportunities of targeting the aberrant 
transcription factor which drives EWFT by exploiting flaws in EWS-FLI1 driven 
reprograming.   
Brenner and colleagues (100) and the Genomics of Drug Sensitivity in Cancer 
(GDSC), a high-throughput drug screening platform (101), first demonstrated in 2012 that 
EWSR1-FLI1- translocated ES display hypersensitivity to Poly(ADP-ribose) polymerase 
inhibition (PARP1i); this has since been replicated by several other groups (98, 99, 102). 
These data have provided a promising drug target for EWFTs, with corresponding FDA-
approved PARP1 inhibitors (83).  However, in the initial clinical study of olaparib in ES, 
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no objective responses were observed in 12 evaluable patients (83). While there were no 
objective responses, 4/12 patients achieved stable disease, with 2 of the 4 achieving minor 
responses (tumor shrinkage of 9% and 12%), indicating a modest level of efficacy via 
PARP1 inhibition in these patients. 
Based on the hypersensitivity of ES to PARP1i in vitro and signs of activity in ES 
patients with olaparib, we sought to identify upfront resistance mechanisms to PARPi 
therapy as well as a rational drug combination that could overcome these mechanisms. We 
and others have shown that a low apoptotic response, even in the presence of growth arrest, 
mitigates response to targeted therapies (87, 103-107). We therefore hypothesized that 
mitigated responses of PARPi may be due to loss of apoptotic potential of EWFTs, which 
could prove particularly true in the chemo-refractory population. This hypothesis was 
further supported by the fact that deficient DNA damage repair is thought to contribute to, 
if not define, PARPi sensitivity in ES (99), as well as the established role of anti-apoptotic 
BCL-2 family proteins in protecting cancer cells from DNA damage-induced apoptosis 
(104, 108) and their inverse correlation of expression to cytotoxic agent sensitivity (8). 
 
Results 
A chemotherapy-naive and chemotherapy-resistant cell line pair respond differently 
to olaparib 
Olaparib performed poorly in ES patients (83) whose tumors were heavily pre-
treated and chemotherapy-resistant. We therefore utilized a pair of cell lines established 
from the same patient prior to and following chemotherapy treatment, at tumor relapse: 
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CHLA9 (Children’s Oncology Group), cells were derived from the chemotherapy-naive 
PNET, positive for the EWS-FLI1 translocation, whereas the CHLA10 (Children’s 
Oncology Group) cell line was established after four cycles of induction chemotherapy 
which included cisplatin, doxorubicin, cyclophosphamide and etoposide (109). We first 
assessed whether sensitivity to olaparib was different in the two cell lines. We found that 
the chemotherapy-naive cells were more sensitive to olaparib, as evidenced by a 5-day 
crystal violet viability assay (Fig. 3.1A, left), 72h dose-response curve (Fig. 3.1A, right), 
and IC50 curve (Fig. 3.8A) compared to the chemotherapy-resistant CHLA10 cells (Fig. 
3.1A), despite both cell lines reportedly expressing high levels of PARP1 (8, 110) and 
olaparib inducing similar growth arrest in both the CHLA9 and CHLA10 cells (Fig. 3.8B). 
In addition, similar levels of DNA damage was observed following olaparib treatment in 
both cell lines as evidenced by pH2A/X immunofluorescence staining (Fig. 3.9A and 
3.9B). Furthermore, we confirmed the CHL10 cells were more resistant to chemotherapy 
compared to the CHLA9 cells. (Fig. 3.10A and 3.10B). 
 
Chemotherapy-resistant CHLA10 ES cells do not undergo cell death in response to 
olaparib 
Since the lack of robust apoptotic responses can underlie resistance to both 
chemotherapy and targeted therapies, and the apoptotic response following many 
chemotherapies and targeted therapies is largely governed by the BCL-2 family of proteins 
(103, 106, 111-113), we first explored the relationship between anti-apoptotic BCL-2 
family expression and olaparib response in the CHLA9 and CHLA10 models. Expression 
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of BCL-2 was upregulated (P < 0.05) in the CHLA10 cells compared to the CHLA9 (Fig. 
3.1B and  Fig. 3.10C) relative to the sensitive CHLA9 cells, whereas expression of other 
key BCL-2 family members were not altered (Fig. 3.1B). 
The increase in BCL-2 prompted us to evaluate BCL-2 expression in pre-treatment 
and post- chemotherapy biopsy samples from two ES patients treated at our cancer center. 
Interestingly, we did not detect an increase in BCL-2 expression in these specimens, in 
contrast to the cell line pair, however BCL-XL expression was markedly higher in 
chemotherapy-resistant tumors (Fig. 3.1C) relative to the matched chemotherapy-naive 
samples. These data indicate that BCL-XL is overexpressed in patients’ ES tumors that 
have undergone chemotherapy, and our findings in models of EWFTs implicate BCL-2 as 
a cooperating partner with BCL-XL in resisting apoptosis. 
Together, these data indicated to us that both BCL-2 and BCL-XL may be 
imperative in ES survival. We then moved to chemical interrogation of the cells with 
specific BCL-2 family inhibitors. Surprisingly, despite the increase in BCL-2, we found 
the BCL-2 specific inhibitor venetoclax (114) was unable to effectively sensitize CHLA10 
cells to olaparib (Fig. 3.11A). Since increased expression of BCL-XL is sufficient to induce 
resistance to venetoclax (115-117), we next tested the dual BCL-2/BCL-XL inhibitor 
navitoclax (118, 119) to determine if this agent sensitizes the CHLA10 cells. While 
venetoclax showed little potentiation of olaparib (Fig. 3.11A and 3.11B), navitoclax 
sensitized CHLA10 cells to olaparib treatment compared to venetoclax (P < 0.05), leading 
to a near complete loss of cell viability (Fig. 3.1D), and showing mild synergy (Fig. 
3.11C). Impressively, at low doses of olaparib (1 µM) where there was no single-drug 
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efficacy in the CHLA9 cells, the addition of navitoclax led to substantial loss of cell 
viability (Fig. 3.11D). Similar to venetoclax, the BCL-XL selective inhibitor A-1331852 
(120) was not effective at sensitizing CHLA10 cells to olaparib (Fig. 3.11E). Consistent 
with these findings, we found the CHLA9 cells underwent marked cell death in response to 
olaparib, as measured by cleaved PARP1 (Fig. 3.1E); in contrast, there was a near absence 
of a cell death response in the olaparib-treated CHLA10 cells (Fig. 3.1E). However, the 
addition of navitoclax led to marked cleavage of PARP1 in the presence of olaparib in the 
CHLA10 cells (Fig. 3.1E), despite the lack of modulation of BCL-2, BCL-XL or the related 
MCL-1 (121) by olaparib (Fig. 3.1F). 
These data indicate that EWFTs can lose their sensitivity to olaparib following 
chemotherapy treatment and relapse, underscored by their inability to undergo cell death, 
and can be rescued by the addition of navitoclax. This was further supported by the 
observation that, at low concentrations of olaparib where sensitive CHLA9 cells do not yet 
respond to single-agent olaparib, navitoclax also sensitizes to olaparib (Fig. 3.11D). "In 
addition, the CHLA9 cells have functional p53, while the CHLA10 cells have non-
functioning p53 (32). It is well established that functional p53 is capable of binding to and 
antagonizing the anti-apoptotic functions of BH3 proteins such as BCL-2 and BCL-XL (6, 
122).  In order to rule out p53 as the cause of inherent resistance to olaparib induced 
apoptosis in the CHLA10 cells when compared to the CHLA9 cells, we used siRNA to 
knockdown TP53 in the CHLA9 and found no difference in olaparib sensitivity (Fig. 3.11F 
left), consistent with a previous report (123). To further support the role of BCL-2 and/or 
BCL-XL overexpression in apoptotic resistance to olaparib treatment we overexpressed 
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BCL-2 or BCL-XL in the CHLA9 cells. Here, we saw a significant increase in resistance to 
olaparib treatment in cells overexpressing BCL-2 or BCL- XL compared to the GFP 
controls (P < 0.0001)  (Fig. 3.12A).  Together these data reveal a striking interplay between 
BCL-2/XL inhibition and PARPi in ES. 
 
Navitoclax and Olaparib cooperate to inhibit tumor growth in a CHLA10 mouse 
model 
We next grew CHLA10 tumors in NSG mice, and evaluated single-agent olaparib, 
navitoclax, and the combination of olaparib and navitoclax to see if the in vitro results 
would translate in vivo. Consistent with the cell culture experiments (Fig. 3.1D and E), we 
found the CHLA10 tumors were not sensitive to olaparib or navitoclax as a monotherapy 
compared to their combination (Fig. 3.1G). However, the combination of olaparib and 
navitoclax demonstrated robust inhibition of tumor growth (Fig. 3.1G). This contrasted 
with the venetoclax/olaparib combination, which was ineffective (Fig. 3.1H), consistent 
with the in vitro results (Fig. 3.11A). The olaparib and navitoclax combination did not 
induce substantial weight loss in the mice or any overt signs of toxicity, suggesting the 
combination is well tolerated (Fig. 3.12B).  
To assess possible hematologic toxicity when using olaparib and navitoclax in 
combination we performed a complete blood count on NSG mice in vivo.  Red blood cell 
and reticulocyte counts were not significantly affected by the combination.   We did 
observe a significant decrease in platelet count as well as neutrophil count following 
navitoclax treatment that has previously been reported with its use (114), however, 
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importantly, olaparib did not augment platelet loss at either time point. Also of importance, 
there was no augmentation of neutropenia or other toxicity by the combination compared  
to any single-agent dosing at either time point (Fig. 3.2).  As thrombocytopenia is the 
major dose limiting effect of navitoclax  (124). we also assayed populations of cells 
following a 24hr recovery period after 7 days of treatment. Impressively, these mice nearly 
fully recovered pre-treatment platelet levels (Fig. 3.2). These data demonstrate olaparib 
plus navitoclax may be both effective and tolerated as a novel combination therapy in 
EWFTs.  
 
Most ES cell lines do not undergo marked apoptosis following olaparib therapy 
Following our findings in the CHLA9 and CHLA10 pair, we next expanded to a 
panel of ES cell lines to determine the ability of olaparib to induce apoptosis. A 
kin to CHLA10, these cells had poor apoptotic responses to olaparib (Fig. 3.3A), in 
contrast to the CHLA9 cells. However, all ES cells underwent G2/M accumulation, as 
previously reported (Fig. 3.12C) (96). Caspase 3 activity confirmed both the differential 
apoptosis between the CHLA9 cells and other EWFTs lines, as well as the apoptosis 
sensitization by navitoclax (3.10A). These data suggest our findings of mitigated apoptotic 
responses to olaparib uncovered in the CHLA10 cells extend to other EWFT models. 
We next determined whether these other resistant EWFT models had higher levels 
of BCL-2 or BCL- XL, as our model would predict. Indeed, in comparison to the CHLA9 
cells, these models had higher levels of BCL-2 and/or BCL-XL (Fig. 3.3B), associated with 
their poor apoptotic responses to olaparib (Fig. 3.3A). We have uncovered an important 
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role for both BCL-2 and BCL-XL in olaparib response in EWFT (Fig. 3.1 and 3.3), and it 
would strengthen the case of the importance of BCL-2 and BCL-XL in EWFT survival if 
these cancers were sensitive to pharmaceutical targeting of these two proteins. We 
therefore examined in the updated GDSC screen (www.cancerRxgene.org) whether ES 
cells were more sensitive to navitoclax (Fig. 3.3C) compared to all other solid tumor cell 
lines grouped together. In fact, ES cell lines were substantially more sensitive (P=8.69*10-
5), with 8/21 cell lines demonstrating IC50s of 700nM and below (Fig. 3.3C).  To 
corroborate the sensitivity to navitoclax, we analyzed MCL1 expression which is capable 
of conferring resistance to navitoclax.  Examining RNA expression in sarcomas with 
translocation events using the R2 platform we found EWS-FLI1 translocated sarcomas 
expressed lower levels of MCL1 emphasizing their reliance on BCL2 and BCL2L1 for 
survival (Fig. 3.3D). 
Interestingly, expression of EWS-FLI1 in HEK293T cells led to higher BCL-2 
transcript levels (P < 0.05) compared to the empty vector control, with consistent BCL-2 
protein changes (Fig. 3.13B and S3.7C); the FLI1 target genes EZH2 (81), STEAP1, and 
PRKCB (22, 125, 126) were all significantly upregulated as well (Fig. 3.13B). To further 
evaluate the relationship of FLI1 and BCL-2, we probed the cancer cell line encyclopedia 
(90) and found a positive correlation (P < 0.0001) between FLI1 and BCL-2 (Fig. 3.13D); 
knockdown of EWS-FLI1 confirmed decrease of BCL-2 expression with the expected 
decrease in EZH2 expression (Fig. 3.13E), and de-suppression of the EWS-FLI1 target 
LOX, and STEAP1, NPY1R and PRKCB were all downregulated following EWS-FLI1 
downregulation, albeit not all significantly (22, 125, 126). Altogether, these data further 
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demonstrate the importance of BCL-2 and BCL-XL in EWFTs, which appear to play 
complimentary roles, constituting a critical survival signal for EWS-FLI1 driven EWFT. 
 
Navitoclax sensitizes a panel of ES cells to olaparib 
We moved to validate navitoclax as a sensitizing agent to olaparib in EWFT cells, 
as was determined in the CHLA9 and CHLA10 pair (Fig. 3.1). In fact, we noted marked 
sensitization by navitoclax to olaparib-induced apoptosis in a panel of ES cells as 
evidenced by cleaved PARP1 (Fig. 3.4A) and FACS measurement of Annexin-V positive 
cells (Fig. 3.4B). Consistent with the CHLA pair, apoptosis sensitization was sufficient for 
navitoclax to markedly reduce total viable cells as determined by both crystal violet assays 
(Fig. 3.4C) and 72h cell-viability assays (Figs. 3.4D and 3.4E). These data again indicate 
that olaparib induced apoptosis can be rescued by the addition of navitoclax in ES. 
 
Navitoclax sensitizes ES cells to olaparib by augmentation of DNA damage and 
disruption of BIM complexes 
We next examined the DNA damaging activity of the olaparib/navitoclax 
combination using pH2A/X immunofluorescence staining as a marker for DNA damage. 
Interestingly, the DNA damage observed following olaparib exposure was substantially 
increased (P < 0.0001) with the addition of navitoclax, which by itself did not induce DNA 
damage (Fig. 3.5A and Fig. 3.14A).  These data are consistent with a direct role of BCL-2 
and BCL- XL in the augmentation of DNA damage (127). 
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Navitoclax disrupts BIM:BCL- XL and BIM:BCL-2 complexes, to induce apoptosis 
(106, 128-130), and can sensitize kinase inhibitors in different cancers through modulation 
of the BCL-2 family (reviewed in ref (36)). We therefore asked whether reduction of BIM 
protected from the olaparib/navitoclax combination. As demonstrated in Fig. 3.5B, 
reduction of BIM by siRNA led to a concomitant loss in cleavage of PARP1. 
Immunoprecipitation of BIM complexes verified navitoclax disrupted BIM:BCL-2 
complexes (Fig. 3.5C and Sup. Fig. 3.14B and 3.14C). These data indicate that 
olaparib/navitoclax induce apoptosis in EWFTs through disruption of BIM complexes, 
whereas this complex disruption leads to BIM-mediated apoptosis (130, 131). Together, 
these data demonstrate multiple mechanisms in which navitoclax sensitizes ES to olaparib.  
 
Mouse models of ES are sensitive to Olaparib plus Navitoclax 
To robustly test this novel combination of olaparib and navitoclax, we expanded 
our analyses to three models of ES; the SK-ES-1 xenograft (ATCC® HTB-86™), and two 
patient-derived xenografts (PDXs). Mice were treated daily with olaparib (100mg/kg), 
navitoclax (80mg/kg), or the combination of olaparib (100mg/kg) + navitoclax (80mg/kg). 
In all three models, there was limited activity of either agent when dosed as a 
monotherapy. However, the combination of olaparib and navitoclax markedly inhibited 
tumor growth in the SK-ES-1 model and PDX SA10233 and, impressively, almost 
completely shrank tumors in the other PDX model, SA13542 (Fig. 3.6A and 3.6B). Again, 
the combination did not markedly affect mouse weights or induce any overt signs of 
toxicity (Fig. 3.12B). Assessment of the tumor lysates from the PDX confirmed marked 
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apoptosis induction with the combination, but not single-agents (Fig. 3.6C), and that both 
PDX models expressed BCL-XL and with the SA10233 model expressing high levels of 
BCL-2 (Fig. 3.14D) confirming RNA sequencing data on BCL2 mRNA expression levels 
between the two PDX models (SA10233 3.5045, SA13542 0.672) . These data, along with 
the CHLA10 chemorefractory mouse model (Fig. 3.1G), demonstrate compelling activity 
of the combination of olaparib and navitoclax in vivo. 
 
Discussion 
Through an unbiased high-throughput drug screen, olaparib was discovered to have 
marked in vitro activity in ES (101). Despite several reports demonstrating hypersensitivity 
of ES to PARP1 inhibition (8, 98-100, 102, 132), subsequent clinical evaluation in a 
heavily pre-treated cohort of ES patients with single-agent olaparib showed only modest 
efficacy (83). Here, we demonstrated an important role for deficient apoptosis following 
olaparib therapy in ES, with the anti-apoptoticproteins BCL-2 and BCL-XL playing key 
roles. We believe these experimental findings at least in part explain the disappointing 
clinical data. 
PARP inhibitors prevent single-stranded (ss) DNA break repairs. This mechanism 
underlies PARPi activity in BRCA-deficient cancers, which are inherently deficient in 
double-stranded (DS) DNA break repair (94). In ES, PARPi sensitivity has been proposed 
to occur for several reasons: First, PARP1 expression is higher in Ewing sarcoma (133), 
probably as a direct result of EWS-FLI1 (100, 133), and higher PARP1 expression is a 
cause of enhanced PARP inhibitor sensitivity (134), most likely through the mechanism of 
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PARP trapping at ssDNA breaks (135-137). Second, ES, like BRCA- deficient cancers, 
appear to have a deficient dsDNA repair system (99). Third, FLI1 drives high SLFN11 
expression (138), a gene tightly linked to DNA-damaging agent efficacy (90, 139). Fourth, 
EWS-FLI1 expression is sufficient to increase dsDNA breaks (100). Fifth, EWS-FLI1 
causes R-loop accumulation, increased replication stress and interferes with BRCA1 
function (56). 
Although there are several factors that may have contributed to olaparib’s lack of 
efficacy in patients with chemotherapy-resistant ES, it is likely that a biological resistance 
mechanism served to rescue tumor cells from direct PARP inhibition. We propose that 
there is an inherent deficiency in many ES to undergo apoptosis following olaparib 
treatment resulting from a protective effect of BCL-2 and BCL-XL (Fig. 3.1 and Fig. 3.3). 
Furthermore, exposure and resistance to chemotherapy appears to contribute to this state of 
apoptotic resistance to olaparib, as evidenced by our results in the CHLA10 cell line (Fig. 
3.1E and 3.3A) and observations in patients’ tumor specimens (Fig. 3.1C). It is likely that 
DNA damaging agents used in induction chemotherapy lead to additional pressure on the 
ES tumor and, as a result, the emergence of cells particularly reliant on BCL- 2/BCL-XL 
for survival. Overall, further studies will be necessary to elucidate the precise relationship 
between these pro-survival BCL-2 members and ES tumorigenesis. 
The strategy to sensitize ES to PARPi via BCL-2/BCL-XL co-inhibition is different 
from other explored strategies to sensitize ES to PARPi; these include the addition of DNA 
damaging agents that intensifies the amount of active DNA damage in the cell, like 
irinotecan and temozolomide (102). Temozolomide has also been demonstrated to enhance 
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PARP1 trapping (137) and, interestingly, the combination of temozolomide and PARPi 
cooperatively downregulates MCL-1, sensitizing to mitochondrial-mediated death (102). 
Although temozolomide-PARPi combinations are poorly tolerated in preclinical ES mouse 
models (99), irinotecan delivered to an orthotopic ES mouse model in dosing schedules 
consistent with the pediatric population demonstrated marked activity (99). Consistent with 
these results, the combination of the PARPi veliparib and irinotecan was well tolerated in a 
recent phase I trial, including reaching a dose sufficient for PARP inhibition in adult 
cancers (140). Interestingly, BCL-XL blocks the ability of irinotecan to induce apoptosis 
and BCL-XL inhibition results in a switch from irinotecan-induced senescence to apoptosis 
(141). Therefore, it is possible that PARPi/irinotecan combinations in other ES models will 
face the same issues we have found PARPi monotherapy to face, namely a refractory 
apoptosis response. The PARPi/irinotecan combination is currently being evaluated in 
pediatric patients with solid tumors (NCT02392793). 
The BCL-2 family of proteins monitors the integrity of the mitochondria and 
integrates the signals of many pathways at the mitochondria (142).  Importantly, Javaheri 
and colleagues (59) elegantly demonstrated that EWS-FLI1 overexpression in 
mesenchymal stem cells, the presumed cell of origin for ES, was sufficient for blocking 
differentiation but led to high rates of apoptosis; retrovirus containing BCL-2, BCL- XL or 
MCL-1 expression plasmids was able to rescue apoptosis, and importantly, led to sarcoma 
formation, which was not accomplished in the parallel, control transduced cells. These data 
together with the data in this manuscript present a compelling case where anti-apoptotic 
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activity of BCL-2 family members, particularly BCL-2 and BCL- XL, play an intricate role 
in ES tumorigenesis and impact ES therapy. 
It has been well known for several decades that BCL-2 has a protective role against 
DNA damage-induced apoptosis (127, 143). Additionally, BCL-XL expression has been 
reported tocorrelate inversely with the sensitivity of cancer cell lines to multiple anti-tumor 
agents, including those acting via a DNA-damaging mechanism (8). This becomes 
particularly relevant in the light that ES have deficient DNA damage responses (99). 
Adding to the intrigue, Khan and colleagues recently reported 13% of patients with ES 
have germline loss-of-function mutations in DNA repair genes (95). It is therefore 
tempting to speculate that, in order for EWS-FLI1- translocated ES to develop and thrive, 
there must be an acquired reliance on the anti-apoptotic proteins BCL-2 and BCL-XL to 
maintain survival. Consistent with this notion, our analyses of HTS data revealed 
navitoclax has substantial single-agent activity (IC50 less than 700nM) across ~40% of ES 
cell lines (Fig. 3.3C). 
This notion is further supported by our findings in the CHLA cells derived from a 
patient prior to and following chemotherapy treatment. The post-chemotherapy CHLA10 
cells, derived at progressive disease, had higher BCL-2 expression relative to the matched 
chemotherapy-naive CHLA9 cells (Fig. 3.1B) and, unlike CHLA9 cells, failed to undergo 
cell death following olaparib therapy (Fig. 3.1E and 3.3A). It is important to note that we 
did not account for other changes that occurred during the acquisition of chemotherapy 
resistance in this model, which could contribute to the resistance of these cells to olaparib. 
For instance, Sorensen and colleagues demonstrated the CHLA10 cells have enhanced flux 
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compared to the CHLA9 cells through the PI3K pathway, which is a result of increased 
ErbB4 expression (144) and which may be contributing to olaparib resistance. 
Notwithstanding, the fact that navitoclax was sufficient to re-sensitize the cells to olaparib 
reflects the importance of BCL-2 and BCL-XL. Interestingly, in the chemotherapy-naive 
CHLA9 cells, where olaparib was very effective (Fig. 3.1A), navitoclax fully sensitized 
these cells to a low dose of olaparib (Fig. 3.11D), which did not have marked single agent 
anti-cancer activity. These data reveal an important interplay between PARP inhibition and 
BCL-2/XL inhibition, which likely contributes to the impressive activity of dual PARP and 
BCL-2/XL inhibition in ES (Figures. 3.1, 3.3 and 3.4), and, again, supports the notion that 
BCL-2 and BCL-XL are important to counteract the intrinsic deficiencies in ES DNA 
damage repair, which are exacerbated by PARP inhibition. Indeed, BCL-2/BCL- XL 
inhibition causes accumulation of DNA damage following PARP inhibition (Fig. 3.9A and 
Fig. 3.13A). Therefore, the robust activity of PARP inhibition and navitoclax is most likely 
due to both BCL-2 and BCL- XL inhibition making these cells more vulnerable to DNA 
damage-induced apoptosis, but also increasing the DNA damage itself. The result is a 
substantial increase in apoptosis (Fig. 3.4A-B), mediated by BIM (Fig. 3.5B and 3.5C), 
which translates to impressive in vivo activity.  
Overall, we demonstrate ES tumors do not undergo a marked apoptotic response 
following olaparib therapy; however, co-targeting BCL-2 and BCL-XL dramatically 
sensitizes these tumors to olaparib in several mouse models of ES, including 
chemotherapy-resistant ES and two PDX models of ES. As we found neither drug 
augmented hematological toxicity of the other (Fig. 3.2), and rational navitoclax-based 
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combinations with other targeted therapies are ongoing in clinical trials (e.g. 
NCT02520778), evaluation of PARP inhibitors and navitoclax in ES are warranted. 
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Figure 3.1 Chemotherapy-resistant EWFT are sensitized to olaparib with the Inhibition of 
BCL-2 and BCL- XL  
 
(A) (left) Crystal violet staining of CHLA9 and CHLA10 after 5-day treatment showing 
sensitivity to no treatment control (no rx) or 5 µM olaparib. (145) 72 hour CellTiter Glo of 
CHLA9 and CHLA10 using the indicated concentrations of olaparib. (B) Western blot 
analysis of the indicated antibodies in chemotherapy-naive and chemotherapy-resistant  
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Figure 3.1 continued 
 
paired lines. (C) Two cases of Ewing sarcoma with available paired primary and recurrent 
metastatic tissues were immunostained for BCL-2 and BCL-XL.  In both cases, similar 
expression of BCL-2 was noted in primary. For BCL-XL, however, increased expression 
was noted in both recurrences compared to the primary tumor. Case 1: Primary: Archival 
sections of the untreated biopsy of the primary tumor (patella), which was localized at 
presentation. Recurrence: Lung metastasis 5 years subsequent, after systemic 
chemotherapy (VAC-IE) and localized radiotherapy to the patellar primary site. Case 2: 
Primary: Archival sections of the biopsy of the untreated primary tumor (thoracic spine), 
which was metastatic (rib, lung, bone marrow) at presentation. Recurrence: Bone 
metastasis (right humerus) 8 months subsequent, after systemic chemotherapy (VAC-IE) 
and localized radiotherapy to the primary and multiple metastatic sites. (D) Crystal violet 
staining showing olaparib resistant CHLA10 cells after 5-day treatment with no treatment 
control (no rx), 5 µM olaparib, 1 µM navitoclax or the combination of 5 µM olaparib + 1 
µM navitoclax. (E) Western blot analysis of apoptosis indicated by an increase in cleaved 
PARP1 in CHLA9 and CHLA10 cells after 24 hour treatment with no treatment control 
(no rx), 5 µM olaparib, 1 µM navitoclax, or 5 µM olaparib + 1 µM navitoclax. (F) Western 
blot analysis of the indicated antibodies in the CHLA9 and CHLA10 cell lines after 24 
hour treatment with no treatment control (no rx), 5 µM olaparib, 1 µM navitoclax, or 5 µM 
olaparib + 1 µM navitoclax.  (G) CHLA10 xenografts treated daily with olaparib 
(100mg/kg), navitoclax (80mg/kg), or the combination of olaparib (100mg/kg) + 
navitoclax (80mg/kg) for 28 days. Error bars are +SEM. Asterisks indicate a significant 
separation between the combination (olap/nav) and all other treatment cohorts using the 
student’s t test (P < 0.05) (H) CHLA10 xenografts treated daily with olaparib (100mg/kg), 
venetoclax (100mg/kg), or the combination of olaparib (100mg/kg) + venetoclax 
(100mg/kg) for 27 days. Error bars are +SEM 
 
 
45 
 
 
Figure 3.2 Combination of olaparib and navitoclax does not augment toxicity 
 
 (A) NSG mice were treated with a no treatment control (no rx), olaparib (100mg/kg), 
navitoclax (80mg/kg), or the combination of olaparib (100mg/kg) + navitoclax (80mg/kg).  
After the indicated 3 or 7 day treatment period, blood was collected and sent to IDEXX 
BioResearch (idexxbioresearch.com) for a complete blood count.  The recovery cohort was  
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Figure 3.2 continued 
 
treated for 7 days with the combination of olaparib (100mg/kg) + navitoclax (80mg/kg) 
and allowed 24 hours without treatment before blood was collected.  Asterisks indicate a  
significant separation between 7 day treatment with olaparib + navitoclax and 7 day 
recovery using the Student’s t Test (P<0.05).  3 day treatment with navitoclax not 
significant compared to 3 day treatment with the combination olaparib + navitoclax, 
neither was 7 day navitoclax compared to 7 day olaparib + navitoclax.   
 
 
 
 
 
 
 
 
 
47 
 
 
Figure 3.3 EWFT are resistant to olaparib which correlates with increased BCL-2 and 
navitoclax sensitivity  
 
(A) FACS analysis of apoptosis after 24 hour treatment with 5 µM olaparib. Error bars are 
+SEM. Asterisks indicate a significant separation between olaparib treatments in the 
CHLA10 cells compared to CHLA9 cells, using the student’s t test (P < 0.05) (B) Western 
blot analysis of the indicated antibodies in EWFT cell lines. (C)  IC50 of navitoclax plotted 
for solid tumor cell lines and 21 Ewing Sarcoma cell lines from 
http://www.cancerrxgene.org/. A Mann-Whitney non-parametric test was performed 
(P=8.69*10-5) (D) ) MCL-1 RNA expression in sarcomas with translocation events (34).  
.  
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Figure 3.4 Combination of olaparib and navitoclax is effective in multiple EWFT cell lines  
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Figure 3.4 continued 
 
(A) Western blot analysis of apoptosis indicated by cleaved PARP1 after 24 hour treatment 
with no treatment control (no rx), 5 µM olaparib, 1 µM navitoclax, or 5 µM olaparib + 1 
µM navitoclax. (B) FACS analysis of apoptosis after 24 hour treatment with 5  
µM olaparib, 1 µM navitoclax, or 5 µM olaparib + 1 µM navitoclax. Percent of apoptosis 
induced by drugs is normalized to the no treatment control. Error bars are +SEM. (C) 
Crystal violet staining after 5-day treatment with 5 µM olaparib, 1 µM navitoclax, or 5 µM 
olaparib + 1 µM navitoclax. (D) Dose response curves in ES cell lines after 72 hour 
treatment with increasing concentrations of olaparib. Viability was determined using 
CellTiter-Glo. Data is graphed as percent viable cells from no treatment control (no rx), 
performed in quadruplicate. Error bars are +SEM. (E) ES cell lines after 72 hour treatment 
with 1 µM navitoclax or 1 µM navitoclax in the presence of increasing concentrations of 
olaparib and viability was determined using CellTiter-Glo. Data is graphed as percent 
viable cells from no treatment control (no rx), performed in quadruplicate. Error bars are 
+SEM.  
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Figure 3.5 DNA damage is increased with the combination of olaparib and navitoclax 
(A) Quantification of immunofluorescence images probed for γH2A.X foci intensity 
following 24 hour treatment using no treatment control (no rx), 5 µM olaparib, 1 µM 
navitoclax, 5 µM olaparib + 1 µM navitoclax or 1 µM etoposide. Error bars are +SEM.  
Asterisks indicate a significant separation between olaparib treatment and the combination 
olaparib + navitoclax.  Significance was determined using the Mann-Whitney U test. (B) 
siRNA knockdown of BIM or control (scramble sequence) in ES4 and A673 cell lines 
followed by 24 hour treatment with either no treatment control (no rx) or 5 µM olaparib + 
1 µM navitoclax (Nav/Olap). (C) An immunoprecipitation of lysates from A673 cells using 
either a BCL-2 antibody or an IgG control antibody (left) and the whole cell lysates (5% 
input) (145), after 4 hour treatment with 5 µM olaparib, 1 µM navitoclax, or 5 µM olaparib 
+ 1 µM navitoclax. 
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Figure 3.6 Olaparib and navitoclax combination is effective in Mouse Models of EWFT 
 
(A) SK-ES-1 xenografts treated daily for 26 days (top) and patient-derived xenografts 
(bottom) treated daily for 31 days (PDX SA13542) or 27 days (PDX SA10233) with 
olaparib (100mg/kg), navitoclax (80mg/kg), or the combination of olaparib (100mg/kg) + 
navitoclax (80mg/kg). Error bars are +SEM. Asterisks indicate a significant separation 
between the combination (olap/nav) and all other treatment cohorts using the student’s t  
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Figure 3.6 continued 
 
test (P < 0.05) (B) Fold change in tumor volume, please note data is from the experiment 
shown in Fig. 4A (PDX SA13542) after 31 days of treatment and the x axis denotes  
individual xenografts. (C) Western blot analysis of cleaved PARP1 from PDX tumor 
lysates after 3 daily treatments of no treatment control (no rx), olaparib (100mg/kg), 
navitoclax (80mg/kg) or the combination of olaparib (100mg/kg) + navitoclax (80mg/kg). 
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Figure 3.7 Melting Curves  
 
(A) Indicated primer melting curves taken from 293T EWS-FLI1 expressing cells during 
RT-qPCR 
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Figure 3.8 A chemotherapy-naive and chemotherapy-resistant cell line pair respond 
differently to olaparib  
 
(A) IC50 curve of CHLA9 and CHLA10 cells following 72 hour treatment with the 
indicated concentrations of olaparib. (B) Cell cycle analysis after 24, 48 and 72 hour 
treatment with 5 µM olaparib, compared to no drug treatment control (No Rx). 
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Figure 3.9 Olaparib induces similar levels of DNA damage in CHLA9 and CHLA10 
 (A) Representative immunofluorescence images showing γH2A.X foci following 72 hour 
treatment of 5 µM olaparib compared to no treatment control (No Rx). (B) Quantification 
of immunofluorescence images probed for γH2A.X intensity following 72 hour treatment 
of 5 µM olaparib compared to no treatment control (No Rx).  Error bars are +SEM, 
asterisks indicate significance between the no treatment control and olaparib treatment for 
CHLA9 or CHLA10, as determined using the Mann-Whitney U test. 
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 Figure 3.10 A chemotherapy-naive and chemotherapy-resistant cell line pair respond 
differently to chemotherapeutics  
 
(A) CellTiter Glo of CHLA9 and CHLA10 cells after 72 hour treatment with increasing 
concentrations of Etoposide and Doxorubicin.  Data is graphed as percent viable cells from 
no treatment control, performed in quadruplicate.  Errors bars are +SEM.  (B)  IC50 curves 
representing the data collected in (A). (C) Quantification of BCL-2 protein expression 
represented in Figure 1B,  (n=3).  Asterisk indicates a significant separation between 
CHLA9 and CHAL10 BCL-2 protein expression, and significance was determined using 
the Student’s t test (P < 0.05). 
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Figure 3.11 Navitoclax sensitizes EWFT to olaparib  
 
(A), (B) CellTiter-Glo of CHLA10 (A) and CHLA9 (B) cells after 72 hour treatment with 
1 µM venetoclax or 1 µM navitoclax with increasing concentrations of olaparib. Data is 
graphed as percent viable cells from no treatment control, performed in quadruplicate. 
Error bars are +SEM.  Asterisks indicate a significant separation between the indicated  
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Figure 3.11 continued 
 
concentrations of venetoclax + olaparib compared to navitoclax + olaparib.  Significance 
was determined using the Mann-Whitney U test. (C) (left) CellTiter Glo viability after 24 
hour treatment with the indicated concentrations of olaparib and navitoclax. (145) Percent 
over the bliss score. Positive scores (red) indicate synergy, negative scores (blue) indicate 
antagonism. All concentrations are presented as µM. (D) Crystal violet staining after 5 day 
treatment showing sensitivity to the indicated drug treatments (E) FACS analysis of 
apoptosis in CHLA10 cells after 24 hour treatment with 1 µM of the BCL-XL inhibitor A-
1331852, 5 µM olaparib, 5 µM olaparib + 1 µM A-1331852, 1 µM navitoclax, or 5 µM 
olaparib + 1 µM navitoclax. Percent of apoptosis induced by drugs is normalized to the no 
treatment control (No Rx). Error bars are +SEM. Asterisks indicate a significant separation 
between navitoclax and olaparib + navitoclax.  There was no significance between the A-
1331852 treatment compared to olaparib + A-1331852.  Significance was determined 
using the Student’s t Test (P<0.05). (F) (left) CellTiter Glo analysis after 72 hour treatment 
with the indicated olaparib concentrations in CHLA9 cells expressing siScramble or 
siTP53.  Error bars are +SEM and there is no significance. (145) Western blot analysis 
confirming siRNA knockdown of p53 protein in CHLA9 cells. 
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Figure 3.12 Olaparib sensitivity is modulated by BCL2 family expression  
 
(A) (left) Western blot analysis of BCL-2 and BCL-XL, confirming over expression in 
CHLA9 cells. (145) CellTiter Glo assay after 24 hour treatment with 5 µM olaparib in 
CHLA9 cells over expressing GFP, BCL-2, or BCL-XL.  Asterisks indicate a significant 
separation between the GFP control, and BCL-2 cells treated with olaparib or BCL- XL 
cells treated with olaparib. Student’s t test was performed.  (B) Average measurement of 
mouse weight (grams) per condition (n=5 mice or greater per condition) over the course of 
each in vivo experiment. Please note, this data was obtained from the efficacy experiments 
shown in Fig. 1F and Fig. 4A, respectively. (C) Cell cycle analysis after 24 hour treatment 
with 5 µM olaparib in the indicated cell lines, compared to no drug treatment controls cells 
(No Rx). 
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Figure 3.13 EWS-FLI1 increases BCL-2 expression in EWFT  
 
(A) Cleaved Caspase-3 activity after 24 hour treatment with the indicated drugs: 5 µM 
olaparib, 1 µM navitoclax, or 5 µM olaparib + 1 µM navitoclax, compared to no treatment  
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Figure 3.13 continued 
 
control (No Rx).  Activity is presented as Relative Fluorescent Units (RFU).  Experiments 
were performed in quadruplicate and error bars are plotted as +SEM.  Asterisks indicate a 
significant separation between the no treatment control and each individual treatment.  
Significance was determined using the Student’s t Test. (B) RNA expression of the 
indicated genes in pl4-EWS-FLI1 or pl4-Empty Vector expressing 293T cell lines. 
Asterisks indicate a significant separation between the empty vector control and the EWS-
FLI1 expressing cells and was determined using the Student’s t Test. (C) Western blot 
comparison as detected by the indicated antibodies in pl4-EWS-FLI1 and pl4-Empty 
Vector 293T cell lines. (D) BCL-2 RNA expression from the (CCLE) in high (n=208) and 
low (n=829) FLI1 expressing tumors. Individual cell lines are represented by a single dot. 
A Mann-Whitney non-parametric test was performed for significance. (E) RNA expression 
of the indicated genes after shRNA knockdown of EWS-FLI1 or control (scramble 
sequence) in A673 and EW16 cell lines. Asterisks indicate a significant separation between 
the shScramble control and the EWS-FLI1 knockdown cells, significance was determined 
using the Student’s t Test. 
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Figure 3.14 DNA damage is increased with the combination of olaparib and navitoclax 
 
 (A) Representative immunofluorescence images showing γH2A.X foci following 24 hour 
treatment 5 µM olaparib, 1 µM navitoclax, 5 µM olaparib + 1 µM navitoclax,1 µM  
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Figure 3.14 continued 
 
etoposide (serving as a positive control), or no treatment control (No Rx). (B)  
Densitometry quantification of BCL-2 levels from the whole cell lysates in Fig. 5C 
normalized to GAPDH.  (C) Western blot analysis with the indicated antibodies after 24 
hour treatment of 5 µM olaparib, 1 µM navitoclax, 5 µM olaparib + 1 µM navitoclax or no 
treatment control (No Rx). (D)  Tumor lysates from control PDX and cell line xenograft 
models were analyzed by Western blot with the indicated antibodies.   
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Chapter 4 – Pharmaceutical Means of Targeting the Fusion Oncogene EWS-FLI1 in 
the Ewing Family of Tumors 
 
Introduction 
Pediatric cancers often have a low mutation burden which suggests epigenetic 
mechanisms may play major roles in driving tumorigenesis (146).  It is well known that 
EWS-FLI1 induces a myriad of epigenetic changes, including global increases in H3K27ac 
a marker for enhanced gene activation, which was the most highly regulated histone mark 
following exogenous EWS-FLI1 expression in mesenchymal stem cells (the potential cell 
of origin for EWFT), including within enhancer regions bound by FLI1 (24, 26, 39, 67). 
This would suggest EWS-FLI1 driven changes in H3K27ac are responsible for the 
activation of FLI1 target genes.  In the same study it was found that H3K27 methylation 
(H3K27me) did not associate with EWS-FLI1 binding, and it is evident that altering 
H3K27me has an inactivating effect on H3K27ac marked gene targets (147, 148).   
We have uncovered an effective therapeutic strategy to target the EWS-FLI1 
program by exploiting a hypersensitivity to the inhibition of H3K27 demethylases using a 
high-throughput pharmacological screen (13).  We demonstrate that H3K27 demethylase 
inhibition is synergistic with RNAP II inhibition, effectively blocking EWS-FLI1 gene 
target activation and resulting in strong anti-EWFT activity.  
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Results 
Drug screen reveals hypersensitivity of EWFT cell lines to GSK-J4 
Utilizing the Genomics of Drug Sensitivity in Cancer (GDSC) platform (13) in a 
high-throughput drug screening, it was revealed that EWFT are acutely sensitive to GSK-
J4 an H3K27 demethylase inhibitor (Fig. 4.1A). Of the ~900 solid tumor cell lines tested, 
21 were EWFT.   Of those EWFT cell lines tested, 12/21 were among the top 25% most 
sensitive and 17/21 were among the top 50% most sensitive cell lines.  GSK-J4 targets the 
histone 3 Lysine 27 demethylases: Ubiquitously transcribed tetratricopeptide repeat, X 
chromosome (UTX), and Jumonji D3 (JMJD3) described in Figure 4.1B.  Upon further 
investigation, we found no correlation between GSK-J4 sensitivity and expression of its 
targets KDM6A (UTX)) and KDM6B (JMJD3), nor was there any correlation with the 
enhancer of zeste homolog 2 (EZH2) (80, 81, 149-151) or other members of the 
polycomb2 repressor complex (PRC2) (data not shown).  Interestingly we found an inverse 
correlation between overall survival and the expression of KDM6B (152, 153), linking 
higher expression to lower overall survival (Fig. 4.1C), and emphasizing its relationship 
with EWFT severity.  
 
GSK-J4 inhibits EWFT growth in vitro by downregulating EWS-FLI1 targets 
To fully characterize the sensitivity of EWFT to GSK-J4 we assessed its activity in 
a panel of EWFT cell lines.  GSK-J4 treatment reduced cell viability in a dose dependent 
manner (Fig. 4.2A) in 72-hour cell viability assays.  We found chemical interrogation with 
GSK-J4 had a robust effect on EWFT cell lines including a near complete loss of cell 
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viability in 5-day clonogenic assays (Fig. 4.2B).  To ensure on-target specificity of GSK-J4 
we utilized western blotting to analyze global histone modifications in cell lines treated 
with GSK-J4 and found, as expected, a subsequent increase in global levels of H3K27 tri-
methylation after treatment with GSK-J4 (Fig. 4.2C).   H3K27 methylation and acetylation 
are closely linked in balancing gene expression, and a loss of H2K27 methylation allows 
for acetylation at the same regions (92, 147, 148, 154-156).  For example, in H3K27M 
mutant diffuse intrinsic pontine glioma (DIPG), which has a reduced H3K27me3 levels, 
there are marked increases in H3K27ac (157, 158). We found the addition of GSK-J4 led 
to global increases in H3K27me3 coupled with a subsequent decrease in H3K27ac (Fig. 
4.2C), while other key histone modifications were unaffected (data not shown). This 
suggests GSK-J4 is able to shift global Histone 3 Lysine 27 epigenetic regulatory marks 
from a highly active to an inactive state and is verified by a decrease in the expression of 
bona fide EWS-FLI1 target EZH2 (Fig 4.2C) (80, 81).   
Using annexin V/propidium iodide staining we assessed the ability of GSK-J4 to 
induce apoptosis in cells using shRNA to knockdown EWS-FLI1.  We found EWS-FLI1 
reduction significantly diminished the ability of GSK-J4 to induce cell death (Fig. 4.2D), 
demonstrating that EWS-FLI1 expression is responsible for sensitizing cells to the 
pharmaceutical inhibition of UTX/JMJD3.  
The EWS-FLI1 translocation is a strong driver of H3K27ac modifications which 
results in gene upregulation (24, 76), therefore we investigated the global expression levels 
of several well characterized EWS-FLI1 target genes: cyclin d1 (CCND1) (39), EZH2, and 
neuropeptide Y receptor Y1 (NPY1R) (24, 26, 97, 159).  Western blot analysis indicates a 
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strong downregulation of the protein levels for these three genes following GSK-J4 
treatment (Fig. 4.3A).   Transcript levels were also markedly decreased after the same 
GSK-J4 treatment conditions (Fig. 4.3B).  Using this data, we hypothesize that the 
H3K27ac marks which can be reduced by GSK-J4 chemical interrogation might overlap 
with those of EWS-FLI1 target gene enhancers, suggesting an epigenetic means of indirect 
EWS-FLI1 inhibition.  
 
GSK-J4 is effective and tolerable in multiple PDX models of EWFT 
To assess the activity of GSK-J4 in vivo we utilized several PDX models derived 
from relapsed EWFT patients (160).  GSK-J4 given once a day (50mg/kg/qd) by 
intraperitoneal injection demonstrated marked anti-tumor activity and was sufficient to 
control tumor growth in all four PDX models (Fig. 4.4A).  Body weight measurements 
indicated no overt signs of toxicity in the mice (weight loss >15% or behavioral changes), 
as demonstrated in Figure 4.4B.  This highlights the single agent efficacy of GSK-J4 as a 
therapy tailored for EWFT and advocates H3K27 demethylase inhibition as a potential 
candidate to test in combination therapy.   
 
CDK7 inhibition sensitizes EWFT to GSK-J4 
Despite the in vivo efficacy of GSK-J4 as a single agent in refractory PDX models 
(Fig. 4.4) we want to enhance the dose response and prevent the possibility of acquired 
drug resistance by using GSK-J4 as a combination therapy.  We have recently 
demonstrated that targeting cyclin dependent kinases (CDK) can inhibit transcription in 
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cancer (161), and often sensitizes to additional therapies (162-164).  It has been well 
documented that the inhibition of transcription is a highly effective treatment in several 
cancer types, and that the EWFTs are sensitive to the very selective CDK7 inhibitor THZ1 
(165, 166), which blocks RNA polymerase II (RNAP II) phosphorylation at serine 5.  We 
rationalize that the use of THZ1 to prevent RNAP II activation would prove a viable drug 
target, working synergistically with GSK-J4 to inhibit EWS-FLI1 driven transcription.   
CDK7 specific inhibitors are well characterized and have shown preferential suppression 
of super-enhancer marked genes (167), which would suggest specificity towards EWS-
FLI1 driven transcripts.    
To assess this hypothesis, we utilized THZ1 in combination with GSK-J4 to 
calculate Bliss Independence dose-response models (91).  We found strong synergy among 
multiple EWFT cell lines as well as four of our ex vivo derived PDX lines (Fig. 4.5A) and 
notably, the combination was effective at concentrations that demonstrated little single 
agent activity.  The observed synergy at concentrations with limited or no single agent 
efficacy suggests concentrations of THZ1/GSK-J4 may be used in combination at lower 
concentrations than those required by single agent treatment for similar efficacy.  Western 
blot analysis further supports this notion as indicated by high expression of cleaved PARP1 
in the combination, paired with marked reduction in global H3K27ac (Fig. 4.5B).     
 
CDK7 inhibition combines with GSK-J4 to cooperatively downregulate EWS-FLI1 
targets 
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To better characterize the mechanisms of sensitivity and specificity towards EWS-
FLI1 gene target regulation, we performed chromatin immunoprecipitation against 
H3K27ac in the A673 cell line and designed primers flanking the FLI1 binding site of 
several EWS-FLI1 target gene enhancers.  Consistent with the histone modifications in 
Figures 4.2C and 4.5B, we found GSK-J4 treatment induced a significant downregulation 
of H3K27 acetylation at putative FLI1 bound enhancers elements (Fig. 4.6A).  We found 
that the well characterized FLI1 target genes NPY1R, EZH2 (26, 69), and NKX2.2 (168) 
had significantly less H3K27ac histone marks at their putative enhancer sites upon 
treatment with GSK-J4 and THZ1 compared to unmodified EWFT no treatment controls, 
which correlates with the global protein changes described in Figures 4.2C and 4.5B .  
These results correlate with RNA transcript levels following the same drug treatments. 
This data further supports our hypothesis that disrupting UTX/JMJD3 activity functions as 
an indirect inhibitor of EWS-FLI1 through the reversal of H3K27 acetylation at EWS-FLI1 
driven genes.   
 
THZ1 and GSK-J4 combine to induce anti-EWFT activity in vivo 
We next sought to evaluate the combination of GSK-J4 and THZ1 in our SA10233 
PDX model of EWFT.  Daily treatment with GSK-J4 (50mg/kg/qd) and THZ1 
(10mg/kg/qd) was sufficient to reduce tumor growth in a controlled manner compared to 
the vehicle and single agent groups (Fig. 4.6B and 4.6C).  In the combination cohort, some 
toxicity was detected with decreases in weight recorded during the final two data collection 
timepoints.   
70 
 
 
Discussion 
The Ewing Family of Tumors is defined by EWS/ETS translocations which drive 
tumorigenesis (20, 123).  The most abundant translocation being EWS-FLI1 which 
initiates transcriptional reprograming, resulting in a loss of tumor suppressors and the 
activation of oncogenes (24, 76, 169).  Despite the promising therapeutic opportunity that a 
single driver event presents, successful targeting of the EWS-FLI1 transcription factor 
remains elusive.   
Recent studies have shown that EWS-FLI1 drastically alters the epigenome and 
emphasis has been placed on targeting histone modifications as an effective anticancer 
therapy. Several targeting strategies are currently being investigated which seek to reverse 
specific epigenetic dysregulations caused by EWS-FLI (80, 169-173).  Parrish and 
colleagues (174) recently demonstrated that the pan-Jumonji-domain histone demethylase 
inhibitor JIB-04 can dysregulate the EWS-FLI1 oncogenic program.  However, pan 
Jumonji histone demethylase inhibition results in the upregulation of H3K4me3 (through 
the inhibition of Lysine Demethylase 5A) which is associated with increased transcription 
and can lead to the expression of not only tumor suppressors but oncogenes, possibly 
diminishing its effectiveness.  Similarly, the Lysine-specific histone demethylase 1 
(LSD1/KDM1A) is also responsible for demethylating H3K4, and EWS-FLI1 utilizes 
LSD1 overexpression to silence tumor suppressors.  The use of LSD1 inhibitor HCI2509 is 
currently being investigated as a potential therapy for EWFT (175).   
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Another approach to target the EWFT epigenome has focused on increasing 
H3K27ac using histone deacetylase (HDAC) inhibitors.  This can lead to growth arrest and 
promote differentiation in EWFT, and has a rescuing effect on tumor suppressors which 
are downregulated by EWS-FLI1 (169, 173).  While these strategies prove the efficacy in 
reversing epigenetic changes caused by EWS-FLI1, they focus on rescuing tumor 
suppressor expression and fail to address H3K27ac mediated activation of oncogenes, 
which are the histone mark most highly regulated by EWS-FLI1 (76).   
Targeting the histone demethylases UTX/JMJD3 causes the accumulation of  
H3K27me3 and results in gene repression.  This strategy differs from other EWFT 
epigenetic therapies currently under investigation, which seek to inhibit HDAC or increase 
H3K4me3 levels to promote the re-expression of tumor suppressors.  Our approach differs 
by silencing EWFT oncogenes directly and does not rely on tumor suppressor function.  In 
fact, HDAC and KDM5A/LSD1 inhibitors have the drawback of promoting oncogene 
expression in addition to tumor suppressors, putting the cells at a disadvantage.  
H3K27me3 accumulation does not rescue tumor suppressor expression, however it serves 
to function as surrogate tumor suppressors by preventing oncogene expression, 
diminishing the need for tumor suppressor reactivation.  Despite the effectiveness of GSK-
J4, there remains both a lack of reliable biomarkers to predict its clinical activity and the 
potential for EWFT to become resistant.  We hope that by utilizing the CDK7 inhibitor 
THZ1 in combination, we can mitigate the development of GSK-J4 resistance.   
In summary, we have uncovered an effective therapeutic strategy to epigenetically 
target the EWS-FLI1 program resulting in reduced FLI1 target gene expression (Fig. 4.7). 
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By inhibiting UTX/JMJD3 in combination with CDK7 inhibition we are able to both drive 
H3K27 modifications towards hypermethylation, subsequently reducing H3K27ac 
activation of EWS-FLI1 targets, and block RNAP II mediated transcription of those same 
genes.  Our studies highlight an effective and promising new epigenetic therapy for the 
treatment of EWFT, however further work is required to support the mechanistic 
relationship and to elucidate the clinical efficacy of these drugs in combination. 
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Figure 4.1 Drug Screen reveals sensitivity of EWFT to GSK-J4 
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Figure 4.1 Continued 
(A) High throughput screen of GSK-J4 measuring viability with resazurin, in collaboration 
with the GDSC.  (B) Graphical representation of GSK-J mechanism, directly targeting the 
histone demethylases JMJD3 and UTX, which are responsible for removing methyl groups 
in opposition to the PRC2 complex. Drug treatment results in global increases in H3K27 
methylation. (C) Survival Analysis of EWFT patients with KDM6B high and low 
expression from the Gene Expression Omnibus GSE17679.  Statistical analysis was 
performed using the log-rank test.  
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Figure 4.2 GSK-J4 reduces cell viability and alters H3K27 marks in EWFT 
(A) 72-hour dose response viability assay with increasing concentrations of GSK-J4,  
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Figure 4.2 Continued 
measured using CellTiter-Glo.  Conditions were measured in quadruplicate. Error bars are 
+SEM. (B) Crystal violet staining after 5-7 day treatment with no treatment (no rx) or 2 
µM GSK-J4.  (C) Western blot analysis of the indicated antibodies, histone modifications 
represent global levels after 72-hour treatment  no treatment (-) or 2 µM GSK-J4. (D) 
FACS analysis of apoptosis after 72-hour treatment with 2 µM GSK-J4 in cell lines 
expression an sh-scrambled sequence, or sh-EWS-FLI1 knockdown.  The percentage of 
induced apoptosis is normalized to the no-treatment controls, error bars are +SEM.  
 
 
 
 
 
77 
 
 
Figure 4.3 EWS-FLI1 driven genes are reduced following GSK-J4/THZ1 treatment 
(A) Western blot analysis of the indicated antibodies of FLI1 target genes after 48-hour 
treatment with no-treatment control (no rx), 1 µM GSK-J4, 6-hour treatment with 10 nm 
THZ1, or 48-hour 1 µM GSK-J4/6-hour 10 nm THZ1. (B) RNA expression of the 
indicated genes following 48-hour treatment with no-treatment control (no rx), 1 µM GSK-
J4, 6-hour treatment with 10 nm THZ1, or 48-hour 1 µM GSK-J4/6-hour 10 nm THZ1. 
Error bars are +SEM.  
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Figure. 4.4 Histone demethylase inhibition slows tumor growth 
(A) Patient-derived xenografts treated daily for the indicated timepoint with vehicle  
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Figure 4.4 Continued  
(DMSO) or GSK-J4 (50mg/kg).  Asterisks indicated a significant separation between 
treatment cohorts using the Student t test (P < 0.05).  Error bars are +SEM (B) Average 
measurements of mouse weight (grams) per PDX over the course of each in vivo PDX 
from figure 4.4A. Error bars are +SEM. 
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Figure 4.5  GSK-J4 and THZ1 synergistically inhibit EWFT cells and ex vivo PDX models 
(A) CellTiter Glo Viability of EWFT cell lines and ex vivo PDX lines, after 48-hour 
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Figure 4.5 Continued 
treatment with the indicated concentrations of GSK-J4 and THZ1. Data presented as 
percent viability and as previously described, depicting percent over the bliss score (91). 
Positive scores (red) indicate synergy, negative scores (blue) indicate antagonism. All 
concentrations are presented as µM. (B) Western blot analysis of the indicated antibodies, 
indicating apoptosis with Cleaved PARP or global changes in histone modifications after 
48-hour treatment with no-treatment control (no rx), 1 µM GSK-J4, 6-hour treatment with 
10 nm THZ1, or 48-hour 1 µM GSK-J4/6-hour 10 nm THZ1.  
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Figure 4.6  The combination of GSK-J4 and THZ1 inhibits EWFT driven gene activation 
and reduces tumor growth 
 
(A) ChIP on the putative enhancer regions of the indicated genes at their FLI1 binding  
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Figure 4.6 Continued 
sites.  Cells were fixed and collected after 48-hour treatment with no-treatment control (no 
rx), 2 µM GSK-J4, 6-hour treatment with 10 nm THZ1, or 48-hour 2 µM GSK-J4/6-hour 
10 nm THZ1 and run using the RT-qPCR conditions described in the materials and 
methods section.  H3K27ac was calculated as a percentage of input, and statistics was 
performed using the Student’s t test.  Error bars are +SEM. (B) (left) Patient-derived 
xenograft SA10233 treated daily for the indicated timepoint with vehicle (DMSO), GSK-
J4 (50mg/kg), THZ1 (10mg/kg), or the combination of GSK-J4 (50mg/kg) + THZ1 
(10mg/kg).  Asterisks indicated a significant separation between treatment cohorts using 
the Student t test (P < 0.05).  Error bars are +SEM (145) Average measurements of mouse 
weight (grams) over the course of the in vivo experiment from figure 4.6A (left). (C) Fold 
change in tumor volume.  Please note the data is from figure 4.6A (left) comparing day 1 to 
day 32.   
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Figure 4.7 Conceptualized mechanism of co-targeting EWS-FLI1 
Cartoon representation of the mechanistic role GSK-J4 plays to inhibit H3K27ac at EWS-
FLI1 driven transcripts, while cooperatively being downregulated by THZ1 mediated 
inhibition of RNAPII activation. (TOP) GSK-J4 reduces EWS-FLI1 driven H3K27ac at 
the enhancer regions of EWS-FLI1 bound target genes, resulting in decreased gene 
activation. (MIDDLE) THZ1 inhibits CDK7 activity, which results in a loss of RNAPII 
phosphorylation at serine 5 and the reduction of oncogenic transcripts.  (BOTTOM) THZ1 
cooperatively blocks EWS-FLI1 driven transcripts, sensitizing EWFT cells to GSK-J4 and 
inhibiting oncogenesis.   
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Chapter 5 – General Discussion 
 
 
 Although the occurrence of EWFT is less common than other forms of cancer, this 
statistic belies its highly aggressive and deadly nature.  Despite recent advances that have 
increased EFS of patients with localized disease, the rate of death in patients who relapse 
or present with metastasis remains unacceptably high (20, 176).  EWFT is unique in that it 
has one of the lowest somatic mutation rates among all cancer types which places the 
burden of oncogenesis mainly on the FET/ETS fusions which are hallmarks of the disease.  
Specifically the t(11;22)(q24;q12) chromosomal translocation which results in the 
formation of the EWS-FLI1 oncoprotein is found in 85% of EWFT cases (31).  Due to  
EWFT’s reliance on FET/ETS translocations, this has been the greatest subject of study for 
disease therapy, however this aberrant transcription factor also presents an improbable 
drug target.  Within the EWFT family there are only a small number of  inactivating 
mutations in tumor suppressors such as p53 or RB, and other inactivating mutations only 
occur in a small subset of the disease such as STAG2 (82).  This further suggests that the 
main effector of oncogenesis is mediated by the transcriptional and epigenetic changes that 
occur as a result of FET/ETS fusions.  The future of EWFT treatment rests in our 
understanding and exploitation of the transcriptional machinery directed by fusions such as 
EWS-FLI1, and how they incur epigenetic dysregulation.  There has been extensive 
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research describing the vast transcription profile of EWS-FLI1 and its many gene targets 
that are dysregulated, however the function and role they play in promoting EWFT 
tumorigenesis remains unknown (73, 76, 133).   
In cancers such as EWFT where no viable targeted therapies are clinically available 
we have to rely on the use of multiple cytotoxic chemotherapeutic agents as the standard of 
care such as VDC-IE in EWFT (32-34).  Despite our best efforts to develop and utilize 
targeted therapies, drug resistance continues to be a challenge.  A perfect example of this is 
EWFT’s reliance on PARP to assist in the repair of DNA damage due to defects in HR 
proteins such as BRCA1.  In normal cells, EWSR1 is able to regulate the formation of R-
loops: DNA-RNA hybrids which stall replication forks.  However, in EWFT cells the 
EWS-FLI1 oncoprotein loses this function, leading to a higher incidence of R-loop 
formation, which have the ability to sequester and inactivate BRCA1, sensitizing the cells 
to cytotoxic and DNA damaging agents such as olaparib (56).  However patients failed to 
respond to single agent PARPi therapy due to an underappreciated resistance to PARP 
inhibition as a result of chemotherapy .  The work presented herein represents the 
development of combination targeted therapies through the inhibition of EWS-FLI1 
machinery and downstream targets.   
However, the efficacy of the discussed targeted therapies should be assessed in 
additional FET/ETS translocations which cause EWFT.  EWSR1 and FUS proteins 
(representing 100% of the known FET/ETS fusions which cause EWFT) are involved in 
resolving R-loop formation to prevent stalled replication machinery and subsequent DNA 
damage, and this function is lost upon FET/ETS fusions (56, 177).  This would suggest 
87 
 
that the reduced BRCA1 activity found in the EWS-FLI1 fusion is likely to be found in the 
entirety of EWFT, as well as their sensitivity to PARP inhibition (94).  In addition, 
members of the ETS family of transcription factors all bind GGAA motifs, suggesting they 
share similar gene targets, and when translocated to a FET protein would result in similar 
profiles of gene dysregulation as demonstrated between EWS-FLI1 and EWS-ERG.  This 
would suggest that the targeted therapies we previously discussed would have efficacy in 
non-EWS-FLI1 translocated EWFT due to analogous genomic and epigenetic 
dysregulation and susceptibilities (27, 43, 55, 57).  This warrants future investigation into 
the efficacy of these therapies in the remaining translocations found in EWFT.  
 We focus on exploiting EWFT reliance on many of the FLI1 target genes and the 
use of combination therapies to prevent acquired resistance, leading to the effective 
inhibition of EWFT.  To this end Chapter 3 reports on a drug combination capable of 
overcoming acquired chemotherapy resistance mediated by EWS-FLI1 gene dysregulation.  
We report  the lack of efficacy towards the PARP inhibitor olaparib was likely mediated by 
an upregulation of the anti-apoptotic protein BCL-2, as seen in our pre/post chemotherapy 
paired EWFT cell lines CHLA9 and CHLA10.  We were able to demonstrate that our 
CHLA10 EWFT derived cell line displayed increased BCL-2 expression as a means of 
avoiding apoptosis and developing chemotherapy resistance, rendering it insensitive to 
PARP inhibitor driven toxicity.  Although we did not investigate whether FLI1 binds the 
BCL2 enhancer or promoter regions to directly upregulate its expression, we did find a 
correlation between expressing the EWS-FLI1 translocation in naïve HEK293T cells and 
an increase in BCL-2 levels.  We were able to demonstrate that the pro-survival proteins 
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BCL-2 and BCL-XL were both capable of resisting olaparib mediated cell death.  Given the 
transcriptome reprogramming that EWS-FLI1 is capable of, the reliance on the anti-
apoptotic proteins BCL-2 and BCL-XL mediated by EWS-FLI1 is likely a common method 
of acquired chemotherapy resistance in EWFT.   To date, the majority of EWFT therapies 
have focused on DNA-damaging agents in combination with PARP inhibitors to enhance 
their effect (97, 98, 102, 132).  Our use of a duel BCL-2/BCL-XL inhibitor to sensitize 
EWFT cells to PARP inhibition represents a novel strategy which differs greatly from 
those currently being investigated.  
Chapter 4 represents a continued investigation of plausible EWS-FLI1 targeted 
therapies, with a focus on epigenetically blocking the EWFT transcription machinery.  
These studies originated from a HTS drug screen which revealed EWFT were among the 
most sensitive cancer type to the histone demethylase inhibitor GSK-J4.  We observed 
similar levels of sensitivity upon chemical interrogation of an EWFT panel of cell lines 
with GSK-J4, and strong efficacy in several PDX models.  This sensitivity was determined 
to result from the shutting down of global gene activation induced by the EWS-FLI1 
translocation and was achieved by preventing H3K27 acetylation through an increase in 
H3K27 methylation.  We verified this mechanism using targeted ChIP and quantified 
H3K27ac levels at FLI1 bound enhancers of several well-known EWS-FLI1 upregulated 
genes.  Among these genes are: NKX2.2, which is required for oncogenic transformation 
and used as a biomarker for EWFT; NPY1R which produces a G Protein coupled receptor 
whose function is currently not entirely understood but is often used as a predictor of 
EWFT metastasis; and lastly EZH2 which has methyltransferase activity and is responsible 
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for altering the active state of chromatin resulting in gene silencing  (24, 26, 81).  Although 
the specific roles that most EWS-FLI1 target genes play in oncogenesis has yet to be 
identified, we feel these genes are representative of the epigenetic dysregulation caused by 
EWS-FLI1 and serve as a basis for the mechanism of GSK-J4 sensitivity.  This work 
represents a novel approach, demonstrating GSK-J4 is capable of indirect specificity to the 
EWS-FLI1 epigenome with powerful anti-tumor activity.   
To avoid possible acquired resistance to GSK-J4 as a monotherapy and enhance its 
anti-tumor potential, we utilized current literature citing CDK inhibitors as a promising 
new therapeutic opportunity in EWFT (165).  By employing a CDK7 inhibitor responsible 
for the phosphorylation of RNAPII during initiation, we sought to co-target EWS-FLI1 
mediated gene transcription.  Our findings demonstrate robust anti-tumor activity against 
EWFT both in vitro and in PDX mouse models.  Further investigation into CDK7 and 
CDK9/12 inhibitors available in clinic is warranted to identify additional small molecule 
inhibitors that synergize with GSK-J4 or the next generation of histone demethylase 
inhibitors.  
 Both THZ1 and GSK-J4 vary significantly in the pharmacodynamic rate at which 
they act, THZ1 activity peaks at 4-6 hours, while GSK-J4 requires several days to affect 
global H3K27me3 levels.  Therefore, changes in dose scheduling may be required to exert 
the greatest synergistic response.  Another potential pitfall to this combination is the effect 
these drugs have on global gene expression levels, which manifested in the form of toxicity 
in our mouse models.  Several of the mice enrolled in the combination cohort of THZ1 and 
GSK-J4 lost substantial weight and displayed signs of distress and discomfort which was 
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followed by mortality in some instances.  Upon autopsy it was revealed that these fatalities 
occurred in mice with excessive Constipation or Obstipation.  These side effects could be 
mitigated pharmaceutically or by altering/lowering the dosing regimen and may have been 
a result of the DMSO used as a solvent in both THZ1 and GSK-J4.  Despite the side 
effects, both drugs demonstrated the ability to control and reduce tumor growth in vivo 
supporting the efficacy of our two step approach to block EWS-FLI1 gene transcription.   
Previous studies to epigenetically target EWS-FLI1 have focused on HDAC 
inhibitors, in order to maintain the activity of tumor suppressors or promote differentiation 
(147, 173, 178).  Our novel approach is the first of its kind to demonstrate the epigenetic 
targeting of EWS-FLI1 through the inhibition of histone methyltransferases.   When paired 
with highly synergistic CDK7 inhibitors, this represents a new and exciting area of future 
research.  
91 
 
 
Literature Cited 
 
1. Chabner BA, Roberts Jr TG. Chemotherapy and the war on cancer. Nature Reviews 
Cancer. 2005;5:65. 
2. DeVita VT, Chu E. A History of Cancer Chemotherapy. Cancer Research. 
2008;68(21):8643. 
3. Joo WD, Visintin I, Mor G. Targeted cancer therapy--are the days of systemic 
chemotherapy numbered? Maturitas. 2013;76(4):308-14. 
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. 
5. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse 
somatic mutation patterns and pathway alterations in human cancers. Nature. 
2010;466(7308):869-73. 
6. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta. 
2009;1787(5):414-20. 
7. Veloria J, Shin M, Devkota AK, Payne SM, Cho EJ, Dalby KN. Developing 
Colorimetric and Luminescence-Based High-Throughput Screening Platforms for 
Monitoring the GTPase Activity of Ferrous Iron Transport Protein B (FeoB). SLAS 
discovery : advancing life sciences R & D. 2019:2472555219844572. 
8. Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, et al. Sarcoma 
Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns 
Associated with Gene and microRNA Expression. Mol Cancer Ther. 2015;14(11):2452-62. 
9. Worthington P, Drake KM, Li Z, Napper AD, Pochan DJ, Langhans SA. 
Implementation of a High-Throughput Pilot Screen in Peptide Hydrogel-Based Three-
Dimensional Cell Cultures. SLAS discovery : advancing life sciences R & D. 
2019:2472555219844570. 
10. Simó-Riudalbas L, Esteller M. Cancer genomics identifies disrupted epigenetic 
genes. Human Genetics. 2014;133(6):713-25. 
11. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17-
37. 
12. Wilks C, Cline MS, Weiler E, Diehkans M, Craft B, Martin C, et al. The Cancer 
Genomics Hub (CGHub): overcoming cancer through the power of torrential data. 
Database : the journal of biological databases and curation. 2014;2014:bau093. 
13. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. 
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker 
discovery in cancer cells. Nucleic acids research. 2013;41(Database issue):D955-61. 
14. Simo-Riudalbas L, Esteller M. Cancer genomics identifies disrupted epigenetic 
genes. Hum Genet. 2014;133(6):713-25. 
15. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077-80; 
discussion 80. 
92 
 
16. Jones RL, Judson IR. The development and application of imatinib. Expert opinion 
on drug safety. 2005;4(2):183-91. 
17. Salesse S, Verfaillie CM. BCR/ABL: from molecular mechanisms of leukemia 
induction to treatment of chronic myelogenous leukemia. Oncogene. 2002;21:8547. 
18. Fausel C. Targeted chronic myeloid leukemia therapy: Seeking a cure. American 
Journal of Health-System Pharmacy. 2007;64(24_Supplement_15):S9-S15. 
19. Esiashvili N, Goodman M, Marcus RB, Jr. Changes in incidence and survival of 
Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End 
Results data. Journal of pediatric hematology/oncology. 2008;30(6):425-30. 
20. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010;11(2):184-92. 
21. Ewing J. Classics in oncology. Diffuse endothelioma of bone. James Ewing. 
Proceedings of the New York Pathological Society, 1921. CA: a cancer journal for 
clinicians. 1972;22(2):95-8. 
22. Surdez D, Benetkiewicz M, Perrin V, Han ZY, Pierron G, Ballet S, et al. Targeting 
the EWSR1-FLI1 oncogene-induced protein kinase PKC-beta abolishes ewing sarcoma 
growth. Cancer Res. 2012;72(17):4494-503. 
23. Renard C, Ranchere-Vince D. [Ewing/PNET sarcoma family of tumors: towards a 
new paradigm?]. Annales de pathologie. 2015;35(1):86-97. 
24. Boulay G, Volorio A, Iyer S, Broye LC, Stamenkovic I, Riggi N, et al. Epigenome 
editing of microsatellite repeats defines tumor-specific enhancer functions and 
dependencies. Genes & development. 2018;32(15-16):1008-19. 
25. Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, et al. 
Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for 
Ewing sarcoma anchorage independent growth. Proceedings of the National Academy of 
Sciences of the United States of America. 2017;114(37):9870-5. 
26. Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suva ML, et al. EWS-
FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress 
enhancer elements in Ewing sarcoma. Cancer Cell. 2014;26(5):668-81. 
27. Im YH, Kim HT, Lee C, Poulin D, Welford S, Sorensen PH, et al. EWS-FLI1, 
EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress 
transcription of transforming growth factor beta type II receptor gene. Cancer Res. 
2000;60(6):1536-40. 
28. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, et al. Mechanism and 
relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 
2013;32(42):5089-100. 
29. Beck R, Monument MJ, Watkins WS, Smith R, Boucher KM, Schiffman JD, et al. 
EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between 
European and African populations. Cancer genetics. 2012;205(6):304-12. 
30. Uchiumi F, Miyazaki S, Tanuma S. The possible functions of duplicated ets 
(GGAA) motifs located near transcription start sites of various human genes. Cellular and 
molecular life sciences : CMLS. 2011;68(12):2039-51. 
31. Grünewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, 
et al. Ewing sarcoma. Nature Reviews Disease Primers. 2018;4(1):5. 
93 
 
32. May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, et al. 
Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. 
PLoS One. 2013;8(12):e80060. 
33. Pretz JL, Barysauskas CM, George S, Hornick JL, Raut CP, Chen Y-LE, et al. 
Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, 
Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based 
Multimodality Therapy. The oncologist. 2017;22(10):1265-70. 
34. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, et 
al. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in 
Adults. The oncologist. 2017;22(10):1271-7. 
35. Charville GW, Wang W-L, Ingram DR, Roy A, Thomas D, Patel RM, et al. 
EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. Modern Pathology. 
2017;30:1312. 
36. Filion C, Motoi T, Olshen AB, Lae M, Emnett RJ, Gutmann DH, et al. The 
EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the 
PPARG nuclear receptor gene. J Pathol. 2009;217(1):83-93. 
37. Frege T, Uversky VN. Intrinsically disordered proteins in the nucleus of human 
cells. Biochemistry and biophysics reports. 2015;1:33-51. 
38. Ng KP, Potikyan G, Savene RO, Denny CT, Uversky VN, Lee KA. Multiple 
aromatic side chains within a disordered structure are critical for transcription and 
transforming activity of EWS family oncoproteins. Proc Natl Acad Sci U S A. 
2007;104(2):479-84. 
39. Boulay G, Sandoval GJ, Riggi N, Iyer S, Buisson R, Naigles B, et al. Cancer-
Specific Retargeting of BAF Complexes by a Prion-like Domain. Cell. 2017;171(1):163-
78.e19. 
40. Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, et al. A Liquid-to-
Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 
2015;162(5):1066-77. 
41. Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. 
Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI 
and reveals novel transcriptional dependencies for oncogenesis. Genes & cancer. 
2019;10(1-2):21-38. 
42. Nunn MF, Seeburg PH, Moscovici C, Duesberg PH. Tripartite structure of the 
avian erythroblastosis virus E26 transforming gene. Nature. 1983;306(5941):391-5. 
43. Fry EA, Mallakin A, Inoue K. Translocations involving ETS family proteins in 
human cancer. Integrative cancer science and therapeutics. 
2018;5(4):10.15761/ICST.1000281. 
44. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. 
Gene. 2003;303:11-34. 
45. Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of 
oncogenic transcription factors in solid tumours. Nature reviews Cancer. 2017;17(6):337-
51. 
94 
 
46. Hart A, Melet F, Grossfeld P, Chien K, Jones C, Tunnacliffe A, et al. Fli-1 is 
required for murine vascular and megakaryocytic development and is hemizygously 
deleted in patients with thrombocytopenia. Immunity. 2000;13(2):167-77. 
47. Spyropoulos DD, Pharr PN, Lavenburg KR, Jackers P, Papas TS, Ogawa M, et al. 
Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted 
disruption of the Fli1 transcription factor. Mol Cell Biol. 2000;20(15):5643-52. 
48. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene 
fusion with an ETS DNA-binding domain caused by chromosome translocation in human 
tumours. Nature. 1992;359(6391):162-5. 
49. Sharrocks AD. The ETS-domain transcription factor family. Nature reviews 
Molecular cell biology. 2001;2(11):827-37. 
50. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, et al. 
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. 
Neoplasia (New York, NY). 2009;11(8):804-11. 
51. Nakano K, Takahashi S. Translocation-Related Sarcomas. International journal of 
molecular sciences. 2018;19(12). 
52. Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, 
et al. Impact of EWS-ETS fusion type on disease progression in Ewing's 
sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the 
cooperative Euro-E.W.I.N.G. 99 trial. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2010;28(12):1982-8. 
53. Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, et al. 
Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the 
Endoplasmic Reticulum Stress Response. Mol Cancer Ther. 2018;17(9):1902-16. 
54. Maroulakou IG, Bowe DB. Expression and function of Ets transcription factors in 
mammalian development: a regulatory network. Oncogene. 2000;19(55):6432-42. 
55. Ginsberg JP, de Alava E, Ladanyi M, Wexler LH, Kovar H, Paulussen M, et al. 
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in 
Ewing's sarcoma. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 1999;17(6):1809-14. 
56. Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, et al. EWS-
FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. 
Nature. 2018;555(7696):387-91. 
57. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 
Fusion Protein Up-regulates Critical Genes in Neural Crest Development and Is 
Responsible for the Observed Phenotype of Ewing&#039;s Family of Tumors. Cancer 
Research. 2005;65(11):4633. 
58. Cidre-Aranaz F, Alonso J. EWS/FLI1 Target Genes and Therapeutic Opportunities 
in Ewing Sarcoma. Frontiers in oncology. 2015;5:162-. 
59. Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, et al. Increased 
survival and cell cycle progression pathways are required for EWS/FLI1-induced 
malignant transformation. Cell Death Dis. 2016;7(10):e2419. 
95 
 
60. Kovar H. Downstream EWS/FLI1 - upstream Ewing's sarcoma. Genome medicine. 
2010;2(1):8-. 
61. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The 
Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator 
and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 1993;13(12):7393-8. 
62. Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, et al. 
Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a 
Vulnerability in Ewing Sarcoma. Cell reports. 2016;14(3):598-610. 
63. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-
FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's 
sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 1998;16(4):1248-55. 
64. Gonzalez I, Vicent S, de Alava E, Lecanda F. EWS/FLI-1 oncoprotein subtypes 
impose different requirements for transformation and metastatic activity in a murine 
model. Journal of molecular medicine (Berlin, Germany). 2007;85(9):1015-29. 
65. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, et al. 
Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in 
Ewing sarcoma: a report from the Children's Oncology Group. Journal of clinical oncology 
: official journal of the American Society of Clinical Oncology. 2010;28(12):1989-94. 
66. Riggi N, Cironi L, Provero P, Suvà M-L, Kaloulis K, Garcia-Echeverria C, et al. 
Development of Ewing&#039;s Sarcoma from Primary Bone Marrow–Derived 
Mesenchymal Progenitor Cells. Cancer Research. 2005;65(24):11459. 
67. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, et al. EWS-FLI-1 
modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell 
reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 2010;24(9):916-32. 
68. Cavazzana AO, Miser JS, Jefferson J, Triche TJ. Experimental evidence for a 
neural origin of Ewing's sarcoma of bone. The American journal of pathology. 
1987;127(3):507-18. 
69. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, et al. EWS-FLI-1 
expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal 
stem cells. Cancer Res. 2008;68(7):2176-85. 
70. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, Taguchi T, et al. 
Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like 
phenotypes to human mesenchymal progenitor cells. Molecular and cellular biology. 
2008;28(7):2125-37. 
71. Amaral AT, Manara MC, Berghuis D, Ordóñez JL, Biscuola M, Lopez-García MA, 
et al. Characterization of human mesenchymal stem cells from ewing sarcoma patients. 
Pathogenetic implications. PloS one. 2014;9(2):e85814-e. 
72. Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, et al. CD99 
inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to 
oncogenesis. The Journal of Clinical Investigation. 2010;120(3):668-80. 
96 
 
73. Patel M, Simon JM, Iglesia MD, Wu SB, McFadden AW, Lieb JD, et al. Tumor-
specific retargeting of an oncogenic transcription factor chimera results in dysregulation of 
chromatin and transcription. Genome Res. 2012;22(2):259-70. 
74. Wang AH, Zare H, Mousavi K, Wang C, Moravec CE, Sirotkin HI, et al. The 
histone chaperone Spt6 coordinates histone H3K27 demethylation and myogenesis. The 
EMBO journal. 2013;32(8):1075-86. 
75. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, 
et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA 
helicase A inhibits growth of Ewing's sarcoma. Nature medicine. 2009;15(7):750-6. 
76. Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schönegger A, Datlinger P, 
et al. Epigenome mapping reveals distinct modes of gene regulation and widespread 
enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell reports. 
2015;10(7):1082-95. 
77. Dylla L, Moore C, Jedlicka P. MicroRNAs in Ewing Sarcoma. Frontiers in 
oncology. 2013;3:65-. 
78. Blackledge NP, Rose NR, Klose RJ. Targeting Polycomb systems to regulate gene 
expression: modifications to a complex story. Nature Reviews Molecular Cell Biology. 
2015;16:643. 
79. Chen S, Ma J, Wu F, Xiong L-J, Ma H, Xu W, et al. The histone H3 Lys 27 
demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. 
Genes & development. 2012;26(12):1364-75. 
80. Cho YJ, Kim SH, Kim EK, Han JW, Shin K-H, Hu H, et al. Prognostic 
implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by 
H3K27me3 in sarcoma. BMC cancer. 2018;18(1):158-. 
81. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, et al. 
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking 
endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A. 
2009;106(13):5324-9. 
82. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic 
landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. 
PLoS genetics. 2014;10(7):e1004475. 
83. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, et al. Phase 
II study of olaparib in patients with refractory Ewing sarcoma following failure of standard 
chemotherapy. BMC Cancer. 2014;14:813. 
84. Gayon J. From Mendel to epigenetics: History of genetics. Comptes rendus 
biologies. 2016;339(7-8):225-30. 
85. Werner RJ, Kelly AD, Issa JJ. Epigenetics and Precision Oncology. Cancer journal 
(Sudbury, Mass). 2017;23(5):262-9. 
86. Damhofer H, Ebbing EA, Steins A, Welling L, Tol JA, Krishnadath KK, et al. 
Establishment of patient-derived xenograft models and cell lines for malignancies of the 
upper gastrointestinal tract. Journal of translational medicine. 2015;13:115-. 
97 
 
87. Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, et al. Epithelial-
to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer 
by Suppressing BIM. Clin Cancer Res. 2018;24(1):197-208. 
88. Hartig SM. Basic image analysis and manipulation in ImageJ. Current protocols in 
molecular biology. 2013;Chapter 14:Unit14.5. 
89. Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, et al. Exploitation 
of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent 
and Specific Targeted Therapy Combination. Cancer Cell. 2016;29(2):159-72. 
90. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. 
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug 
sensitivity. Nature. 2012;483(7391):603-7. 
91. Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, et al. Navitoclax (ABT-
263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer 
Ther. 2012;11(4):1026-35. 
92. Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schonegger A, Datlinger P, 
et al. Epigenome mapping reveals distinct modes of gene regulation and widespread 
enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell reports. 
2015;10(7):1082-95. 
93. Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schonegger A, Schuster M, 
et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nat 
Med. 2017;23(3):386-95. 
94. Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, et al. 
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. 
Proc Natl Acad Sci U S A. 2013;110(42):17041-6. 
95. Brohl AS, Patidar R, Turner CE, Wen X, Song YK, Wei JS, et al. Frequent 
inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. 
Genet Med. 2017;19(8):955-8. 
96. Dale Rein I, Solberg Landsverk K, Micci F, Patzke S, Stokke T. Replication-
induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent 
apoptosis, necrosis and multinucleation. Cell Cycle. 2015;14(20):3248-60. 
97. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, et al. Dual 
targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin 
and SN38 synergistically inhibits Ewing sarcoma cell growth. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 2014;20(5):1190-203. 
98. Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, Erkizan HV, et al. Combining 
PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol 
Cancer Ther. 2013;12(11):2591-600. 
99. Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, et al. 
Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014;9(3):829-41. 
100. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 
inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer research. 
2012;72(7):1608-13. 
98 
 
101. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. 
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 
2012;483(7391):570-5. 
102. Engert F, Schneider C, Weibeta LM, Probst M, Fulda S. PARP Inhibitors Sensitize 
Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial 
Pathway. Mol Cancer Ther. 2015;14(12):2818-30. 
103. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, et al. BIM 
expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer 
Discov. 2011;1(4):352-65. 
104. Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, et al. Failure to induce 
apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and 
PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 2014;74(11):3146-56. 
105. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-
induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 
2015;160(5):977-89. 
106. Costa C, Molina MA, Drozdowskyj A, Gimenez-Capitan A, Bertran-Alamillo J, 
Karachaliou N, et al. The impact of EGFR T790M mutations and BIM mRNA expression 
on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy 
in the randomized phase III EURTAC trial. Clin Cancer Res. 2014;20(7):2001-10. 
107. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM 
deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine 
kinase inhibitors in cancer. Nat Med. 2012;18(4):521-8. 
108. Xie M, Park D, You S, Li R, Owonikoko TK, Wang Y, et al. Bcl2 inhibits 
recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear 
energy transfer radiation. Nucleic acids research. 2015;43(2):960-72. 
109. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma 
and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically 
enhanced by ceramide modulators. Cancer Res. 2004;64(15):5415-24. 
110. Vanden Heuvel JP, Maddox E, Maalouf SW, Reproducibility Project: Cancer B, 
Iorns E, Tsui R, et al. Replication Study: Systematic identification of genomic markers of 
drug sensitivity in cancer cells. Elife. 2018;7. 
111. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative 
mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic 
success in AML. Cell. 2012;151(2):344-55. 
112. Montero J, Letai A. Dynamic BH3 profiling-poking cancer cells with a stick. Mol 
Cell Oncol. 2016;3(3):e1040144. 
113. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, 
et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic 
chemotherapy. Science. 2011;334(6059):1129-33. 
114. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-
199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing 
platelets. Nat Med. 2013;19(2):202-8. 
99 
 
115. Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax 
resistance. Leuk Lymphoma. 2017;58(9):1-17. 
116. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 
but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells 
but not platelets. Br J Haematol. 2013;163(1):139-42. 
117. Wiese C, Pierce AJ, Gauny SS, Jasin M, Kronenberg A. Gene conversion is 
strongly induced in human cells by double-strand breaks and is modulated by the 
expression of BCL-x(L). Cancer Res. 2002;62(5):1279-83. 
118. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a 
potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-8. 
119. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, 
et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients 
with small-cell lung cancer and other solid tumors. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2011;29(7):909-16. 
120. Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. 
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and 
define improved strategies for cancer therapy. Sci Transl Med. 2015;7(279):279ra40. 
121. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al. 'Seed' 
analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-
molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene. 2007;26(27):3972-9. 
122. Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Differ. 
2006;13(8):1256-9. 
123. Takigami I, Ohno T, Kitade Y, Hara A, Nagano A, Kawai G, et al. Synthetic 
siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts 
in a mouse model. Int J Cancer. 2011;128(1):216-26. 
124. Kaefer A, Yang J, Noertersheuser P, Mensing S, Humerickhouse R, Awni W, et al. 
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-
263) induced thrombocytopenia. Cancer Chemother Pharmacol. 2014;74(3):593-602. 
125. Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, et al. STEAP1 is 
associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer 
Res. 2012;10(1):52-65. 
126. Cidre-Aranaz F, Alonso J. EWS/FLI1 Target Genes and Therapeutic Opportunities 
in Ewing Sarcoma. Front Oncol. 2015;5:162. 
127. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. bcl-
2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to 
topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 
1993;53(18):4251-6. 
128. Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, et al. 
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent 
combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A. 
2015;112(11):E1288-96. 
100 
 
129. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 
dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 
2008;111(4):2300-9. 
130. Harada H, Grant S. Targeting the regulatory machinery of BIM for cancer therapy. 
Crit Rev Eukaryot Gene Expr. 2012;22(2):117-29. 
131. Faber AC, Ebi H, Costa C, Engelman JA. Apoptosis in targeted therapy responses: 
the role of BIM. Adv Pharmacol. 2012;65:519-42. 
132. Ordonez JL, Amaral AT, Carcaboso AM, Herrero-Martin D, del Carmen Garcia-
Macias M, Sevillano V, et al. The PARP inhibitor olaparib enhances the sensitivity of 
Ewing sarcoma to trabectedin. Oncotarget. 2015;6(22):18875-90. 
133. Soldatenkov VA, Albor A, Patel BK, Dreszer R, Dritschilo A, Notario V. 
Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription 
factor. Oncogene. 1999;18(27):3954-62. 
134. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic 
profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic 
targets including PARP1. Cancer Discov. 2012;2(9):798-811. 
135. Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino 
EL, et al. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo 
Tolerability and Efficacy of PARP Inhibitors. Mol Cancer Res. 2015;13(11):1465-77. 
136. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of 
PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72(21):5588-99. 
137. Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, et al. 
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and 
Apoptosis in Ewing's Sarcoma. PLoS One. 2015;10(10):e0140988. 
138. Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, et al. SLFN11 Is a 
Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing 
Sarcoma. Clin Cancer Res. 2015;21(18):4184-93. 
139. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. 
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-
damaging agents. Proc Natl Acad Sci U S A. 2012;109(37):15030-5. 
140. LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, et al. Phase 
I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) 
Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in 
Patients with Advanced Solid Tumors. Clin Cancer Res. 2016;22(13):3227-37. 
141. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. 
Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from 
senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin 
Cancer Res. 2003;9(7):2856-65. 
142. Hata AN, Engelman JA, Faber AC. The BCL2 Family: Key Mediators of the 
Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 2015;5(5):475-
87. 
143. Reed JC. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol 
Lett. 1995;82-83:155-8. 
101 
 
144. Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, et al. 
ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013;5(7):1087-
102. 
145. Wright ML, Dozmorov MG, Wolen AR, Jackson-Cook C, Starkweather AR, Lyon 
DE, et al. Establishing an analytic pipeline for genome-wide DNA methylation. Clin 
Epigenetics. 2016;8:45. 
146. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et 
al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-21. 
147. Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, et al. 
Characterization of an antagonistic switch between histone H3 lysine 27 methylation and 
acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic acids 
research. 2010;38(15):4958-69. 
148. Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective 
inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-
rearranged leukemia. Blood. 2015;125(2):346-57. 
149. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. A 
selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. 
Nat Chem Biol. 2012;8(11):890-6. 
150. Kang SC, Kim SK, Chai JC, Kim SH, Won K-J, Lee YS, et al. Transcriptomic 
Profiling and H3K27me3 Distribution Reveal Both Demethylase-Dependent and 
Independent Regulation of Developmental Gene Transcription in Cell Differentiation. PloS 
one. 2015;10(8):e0135276-e. 
151. Benyoucef A, Palii CG, Wang C, Porter CJ, Chu A, Dai F, et al. UTX inhibition as 
selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. 
Genes Dev. 2016;30(5):508-21. 
152. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene 
expression and hybridization array data repository. Nucleic acids research. 
2002;30(1):207-10. 
153. Savola S, Klami A, Myllykangas S, Manara C, Scotlandi K, Picci P, et al. High 
Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior 
Survival in Ewing's Sarcoma Family of Tumour Patients. ISRN oncology. 
2011;2011:168712. 
154. Aranda S, Mas G, Di Croce L. Regulation of gene transcription by Polycomb 
proteins. Science Advances. 2015;1(11):e1500737. 
155. LaMere SA, Thompson RC, Meng X, Komori HK, Mark A, Salomon DR. H3K27 
Methylation Dynamics during CD4 T Cell Activation: Regulation of JAK/STAT and 
IL12RB2 Expression by JMJD3. Journal of immunology (Baltimore, Md : 1950). 
2017;199(9):3158-75. 
156. Wong RWJ, Ishida T, Sanda T. Targeting General Transcriptional Machinery as a 
Therapeutic Strategy for Adult T-Cell Leukemia. Molecules. 2018;23(5). 
157. Hashizume R. Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. 
Neurol Med Chir (Tokyo). 2017;57(7):331-42. 
102 
 
158. Long W, Yi Y, Chen S, Cao Q, Zhao W, Liu Q. Potential New Therapies for 
Pediatric Diffuse Intrinsic Pontine Glioma. Frontiers in pharmacology. 2017;8:495-. 
159. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype 
mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res. 2006;4(11):851-9. 
160. Heisey DAR, Lochmann TL, Floros KV, Coon CM, Powell KM, Jacob S, et al. The 
Ewing family of tumors rely on BCL-2 and BCL-XL to escape PARP inhibitor toxicity. 
Clin Cancer Res. 2018. 
161. Song KA, Hosono Y, Turner C, Jacob S, Lochmann TL, Murakami Y, et al. 
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung 
Cancer to EGFR Inhibitors and Provides a Novel Drug Target. Clin Cancer Res. 
2018;24(22):5658-72. 
162. Alagpulinsa DA, Ayyadevara S, Yaccoby S, Shmookler Reis RJ. A Cyclin-
Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and 
Sensitizes Multiple Myeloma Cells to PARP Inhibition. Molecular cancer therapeutics. 
2016;15(2):241-50. 
163. Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-
Vidal MN, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and 
sensitizes T-cell lymphomas to BCL2 inhibitors. Nature communications. 2017;8:14290-. 
164. Liu X, Gao Y, Shen J, Yang W, Choy E, Mankin H, et al. Cyclin-Dependent 
Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and 
Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel. Molecular cancer 
therapeutics. 2016;15(7):1691-701. 
165. Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, et al. EWS/FLI 
Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer 
cell. 2018;33(2):202-16.e6. 
166. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. 
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 
2014;511(7511):616-20. 
167. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, 
et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in 
MYCN-driven cancer. Cell. 2014;159(5):1126-39. 
168. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, et al. Expression 
profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. 
Cancer Cell. 2006;9(5):405-16. 
169. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, et al. 
Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. International 
Journal of Cancer. 2005;116(5):784-92. 
170. Di Pompo G, Salerno M, Rotili D, Valente S, Zwergel C, Avnet S, et al. Novel 
Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in 
Sarcoma Cancer Stem Cells. Journal of Medicinal Chemistry. 2015;58(9):4073-9. 
171. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic 
inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 
2014;20(12):1394-6. 
103 
 
172. Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, et al. 
Targeted inhibition of histone H3K27 demethylation is effective in high-risk 
neuroblastoma. Sci Transl Med. 2018;10(441). 
173. Souza BK, da Costa Lopez PL, Menegotto PR, Vieira IA, Kersting N, Abujamra 
AL, et al. Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote 
Neural Differentiation in Ewing Sarcoma. Molecular neurobiology. 2018;55(9):7242-58. 
174. Parrish JK, McCann TS, Sechler M, Sobral LM, Ren W, Jones KL, et al. The 
Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and 
increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and 
survival, and reduced tumor growth. Oncotarget. 2018;9(69):33110-23. 
175. Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, et al. 
Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and 
impedes Ewing sarcoma tumor growth. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2014;20(17):4584-97. 
176. Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, et al. Ewing 
Sarcoma: Current Management and Future Approaches Through Collaboration. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
2015;33(27):3036-46. 
177. Richard P, Manley JL. R Loops and Links to Human Disease. J Mol Biol. 
2017;429(21):3168-80. 
178. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, et al. 
Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer. 
2005;116(5):784-92. 
 
 
 
 
104 
 
 
 
VITA 
 
Daniel Andrew Russell Heisey was born in Springfield Virginia on June 19, 1989.  
At a young age he quickly grasped science’s ability to answer life’s many questions, and 
its pursuit eventually him led to Christopher Newport University where he was awarded 
his Bachelor of Science degree in 2011. 
Upon graduation he pursued his longing for science and spent 3 years researching 
Arboviruses for the FDA at the NIH.  It was during this time that he realized his love of 
research and in 2014 began his Doctoral studies in the Biomedical Sciences Doctoral 
Program at Virginia Commonwealth University.  During his first year of studies he joined 
the Translational Oncology lab of Dr. Anthony Faber where he remained to complete his 
degree.   
Service and Awards: 
• Award for Outstanding Student Publication in Biology and Genetics 
Molecular Biology and Genetics Department, May 10, 2019 
 
▪ Excellence in Cancer Research Award  
VCU Massey Cancer Center Research Retreat, June 16, 2017 
 
▪ Ad Hoc Reviewer – Clinical Cancer Research  
 
▪ Promotion and Tenure Committee Member 
Department of Oral and Craniofacial Molecular Biology 
Virginia Commonwealth University, School of Medicine, 2018 
 
▪ Beta Beta Beta, National Biological Honor Society 
Christopher Newport University, Newport News, VA 
105 
 
 
Publications: 
 
1. Heisey DAR, Lochmann TL, Floros KV, Coon CM, Powell KM, Jacob S, Calbert 
ML, Ghotra MS, Stein GT, Maves YK, Smith SC, Benes CH, Leverson JD, Souers 
AJ, Boikos SA, Faber AC (2018). The Ewing family of tumors rely on BCL-2 and 
BCL-XL to escape PARP inhibitor toxicity. Clin Cancer Res. 2018 Oct 22; PMID:  
30348635 
 
2. Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert 
ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, 
Benes CH, Faber AC. Targeted inhibition of histone H3K27 demethylation is 
effective in high-risk neuroblastoma. Sci Transl Med. 2018 May 16; 10(441). 
PMID: 29769286 
 
3. Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, 
Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, 
Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton 
TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, 
Bernstein B, Ebi H, Engelman JA, Faber AC. Epithelial-to-Mesenchymal 
Transition Antagonizes Response to Targeted Therapies in Lung Cancer by 
Suppressing BIM. Clin Cancer Res. 2018 Jan 1; 24(1):197-208. PMID: 29051323 
 
4. Añez, G., Volkova, E., Jiang, Z., Heisey, D. A. R., Chancey, C., and Fares, R. C. 
G. (2017). Collaborative study to establish World Health Organization international 
reference reagents for dengue virus Types 1 to 4 RNA for use in nucleic acid 
testing. Transfusion 57, 1977–1987. doi: 10.1111/trf.14130 
 
5. Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-
Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey 
DAR, Ferrell JT, Bristol ML, March RJ, Yates C, Hicks MA, Nakajima W, Gowda 
M, Windle BE, Dozmorov MG, Garnett MJ, McDermott U, Harada H, Taylor SM, 
Morgan IM, Benes CH, Engelman JA, Mossé YP, Faber AC. Exploitation of the 
Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent 
and Specific Targeted Therapy Combination. Cancer Cell. 2016 Feb 8; 29(2):159-
72. PMID: 26859456 
 
6. Grinev, A., Chancey, C., Volkova, E., Añez, G., Heisey, D.A.R., Winkelman, V., 
Foster, G. A., Williamson, P., Stramer, S. L., Rios, M. (2016). Genetic Variability 
of West Nile Virus in U.S. Blood Donors from the 2012 Epidemic Season. PLoS 
neglected tropical diseases, 10(5), e0004717. doi:10.1371/journal.pntd.0004717 
PMID: 27182734 
 
106 
 
7. Añez, G., Heisey, D.A.R., Chancey, C., Fares, R. C., Espina, L. M., Souza, K. P., 
Teixeira-Carvalho, A., Krysztof, D. E., Foster, G. A., Stramer, S. L., Rios, M. 
(2016). Distribution of Dengue Virus Types 1 and 4 in Blood Components from 
Infected Blood Donors from Puerto Rico. PLoS neglected tropical diseases, 10(2), 
e0004445. doi:10.1371/journal.pntd.0004445. PMID: 26871560 
 
8. Añez, G., Heisey, D.A.R., Volkova, E., & Rios, M. (2016). Complete Genome 
Sequences of Dengue Virus Type 1 to 4 Strains Used for the Development of 
CBER/FDA RNA Reference Reagents and WHO International Standard 
Candidates for Nucleic Acid Testing. Genome announcements, 4(1), e01583-15. 
doi:10.1128/genomeA.01583-15.  PMID: 26868382 
 
9. Anez G, Jiang Z, Heisey DA, Kerby S, Rios M. Collaborative study for the 
characterization of a chikungunya virus RNA reference reagent for use in nucleic 
acid testing. Vox sanguinis. 2015;109(4):312-8 
 
10. Añez, G., Heisey, D.A.R., & Rios, M. (2014). Complete Coding Region Sequence 
of a Chikungunya Virus Strain Used for Formulation of CBER/FDA RNA 
Reference Reagents for Nucleic Acid Testing. Genome announcements, 2(4), 
e00587-14. doi:10.1128/genomeA.00587-14.  PMID: 25081254 
 
11. Añez, G., Heisey, D.A.R., Espina, L. M., Stramer, S. L., & Rios, M. (2012). 
Phylogenetic analysis of dengue virus types 1 and 4 circulating in Puerto Rico and 
Key West, Florida, during 2010 epidemics. The American journal of tropical 
medicine and hygiene, 87(3), 548-53. PMID: 22826483 
 
 
